
==== Front
Cell Mol Biol Lett
Cell Mol Biol Lett
Cellular & Molecular Biology Letters
1425-8153
1689-1392
BioMed Central London

39245718
640
10.1186/s11658-024-00640-3
Review
Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis
Abu Aqel Yasmin 1
Alnesf Aldana 12
Aigha Idil I. 1
Islam Zeyaul 3
Kolatkar Prasanna R. 23
Teo Adrian 456
http://orcid.org/0000-0001-7764-6772
Abdelalim Essam M. emohamed3@sidra.org

12
1 grid.467063.0 0000 0004 0397 4222 Laboratory of Pluripotent Stem Cell Disease Modeling, Translational Medicine Division, Research Branch, Sidra Medicine, P.O. Box 26999, Doha, Qatar
2 grid.418818.c 0000 0001 0516 2170 College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar Foundation, Education City, Doha, Qatar
3 grid.452146.0 0000 0004 1789 3191 Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar
4 https://ror.org/04xpsrn94 grid.418812.6 0000 0004 0620 9243 Stem Cells and Diabetes Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Proteos, Singapore, Singapore
5 https://ror.org/01tgyzw49 grid.4280.e 0000 0001 2180 6431 Department of Biochemistry and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
6 https://ror.org/01tgyzw49 grid.4280.e 0000 0001 2180 6431 Precision Medicine Translational Research Programme (PM TRP), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
8 9 2024
8 9 2024
2024
29 1208 5 2024
23 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Glucokinase (GCK), a key enzyme in glucose metabolism, plays a central role in glucose sensing and insulin secretion in pancreatic β-cells, as well as glycogen synthesis in the liver. Mutations in the GCK gene have been associated with various monogenic diabetes (MD) disorders, including permanent neonatal diabetes mellitus (PNDM) and maturity-onset diabetes of the young (MODY), highlighting its importance in maintaining glucose homeostasis. Additionally, GCK gain-of-function mutations lead to a rare congenital form of hyperinsulinism known as hyperinsulinemic hypoglycemia (HH), characterized by increased enzymatic activity and increased glucose sensitivity in pancreatic β-cells. This review offers a comprehensive exploration of the critical role played by the GCK gene in diabetes development, shedding light on its expression patterns, regulatory mechanisms, and diverse forms of associated monogenic disorders. Structural and mechanistic insights into GCK’s involvement in glucose metabolism are discussed, emphasizing its significance in insulin secretion and glycogen synthesis. Animal models have provided valuable insights into the physiological consequences of GCK mutations, although challenges remain in accurately recapitulating human disease phenotypes. In addition, the potential of human pluripotent stem cell (hPSC) technology in overcoming current model limitations is discussed, offering a promising avenue for studying GCK-related diseases at the molecular level. Ultimately, a deeper understanding of GCK’s multifaceted role in glucose metabolism and its dysregulation in disease states holds implications for developing targeted therapeutic interventions for diabetes and related disorders.

Keywords

Glucokinase
Glucose
Insulin
Diabetes
Mutations
Stem cells
Beta cells
Pancreas
Liver
http://dx.doi.org/10.13039/100019475 Sidra Medicine SDR400216 Abdelalim Essam M. http://dx.doi.org/10.13039/501100001348 Agency for Science, Technology and Research HLTRP/2022/NUS-IMCB-02 OFIRG21jun-0097 CSASI21jun-0006 MTCIRG21-0071 H22G0a0005 I22D1AG053 HLCA23Feb-0031 SC36/19-000801-A044 Teo Adrian issue-copyright-statement© University of Wroclav 2024
==== Body
pmcIntroduction

Glucokinase (GCK) is a member of the hexokinase family, also known as hexokinase IV. It plays an essential role in glucose metabolism, crucial for sustaining blood glucose levels within normal ranges. It is a pivotal metabolic enzyme that catalyzes the first rate-limiting step of glycolysis in the pancreas and liver. GCK is responsible for catalyzing the ATP-dependent phosphorylation of glucose to glucose-6-phosphate (G6P), which triggers insulin secretion in pancreatic β-cells and glycogen synthesis in the liver [1]. GCK is also expressed in other tissues, including the intestine, hypothalamus, pituitary gland, lung, and spleen [2]. Unlike other hexokinases, GCK is characterized by an extremely low affinity for glucose and the lack of inhibition by its end-product, G6P. These characteristics mark GCK as the primary glucose sensor in many vertebrates, including humans [3].

GCK was first discovered as an enzyme in the rat liver and subsequently in the pancreas of obese mice during the 1960s [4, 5]. GCK has subsequently been the subject of intense studies due to its unique sigmoidal response to glucose. The strongest evidence of the GCK’s central role in glucose metabolism was provided in 1992 when a heterozygous GCK-inactivating mutation was reported to cause a mild type of monogenic diabetes (MD) termed maturity-onset diabetes of the young 2 (MODY2) [6]. In addition to MODY2, human genetic analysis established a link between GCK and other forms of MD, including the severe form of permanent neonatal diabetes mellitus (PNDM) caused by homozygous GCK-inactivating mutation(s) [7]. In contrast, mutations that increase GCK activity cause hyperinsulinism (GCK-HI), which is characterized by excessive insulin secretion [8]. Currently, more than 700 mutations in the GCK gene have been reported, distributed throughout its full length. Despite the high number of GCK mutations, around 80 in total have been characterized in vitro [9–12]. Moreover, the functional impact of the majority of GCK mutations remains unresolved.

This review provides an in-depth exploration of the pivotal role played by the GCK gene in the development of diabetes, shedding light on its expression patterns within pancreatic islets and the liver. Furthermore, it elucidates the intricate regulatory mechanisms governing GCK expression, which is crucial for understanding its contribution to diabetes pathogenesis. Furthermore, the article discusses the diverse forms of diabetes arising from GCK mutations and evaluates the potential of human and animal models in unraveling the underlying mechanisms of GCK-related diabetes development.

Structure of GCK and mechanistic overview

The GCK gene is located on the short arm of human chromosome 7, specifically at the region (7p15.3-p15.1), and spans ten exons [9]. In mammals, a critical feature of the GCK gene is the presence of two distinct promoters separated by approximately ~ 30 kbp [1, 13]. The upstream promoter and its associated leader exon drive GCK expression in pancreatic islet cells and other non-hepatic tissues (neuroendocrine isoform). The downstream promoter and its associated leader promoter are active only in the liver [1]. These promoters, with their adjacent exons, specify the synthesis of 5ʹ-UTR of GCK mRNA and the first 15 amino acids of the GCK protein [1, 14]. Therefore, liver GCK protein differs from neuroendocrine GCK at their NH2 terminal ends. Despite this difference, liver and neuroendocrine GCK proteins have similar kinetic properties and are functionally indistinguishable [3, 14]. However, the regulation of GCK expression is distinct in the liver compared with endocrine cells at both transcriptional and posttranscriptional levels [14].

The unique structural characteristics of GCK allow it to act as a glucose sensor and as a crucial regulatory element in many metabolic processes [15]. GCK is a dynamic 52-kDa enzyme consisting of 465 amino acid residues, which fold into a large and a small domain [16]. Between the two domains is a cleft forming the active site where glucose binds. The orientation of the two domains is not static, as GCK exists in multiple conformational ensembles. Kamata and colleagues determined the crystal structure of human GCK using X-ray crystallography, providing explicit support for the model. Under two distinct crystallization conditions, GCK protein crystals were prepared with short truncations at the NH2-terminal end (11 or 15 amino acids), either in the presence of glucose and a ligand or without any ligand. The GCK protein generally comprises two globular domains (large and small) connected by three flexible loops forming a hinge. A narrow, deep cleft is formed between the two domains when glucose and the activator are present (Fig. 1). Both the glucose-binding pocket and the activator-binding site are located in the hinge region [15]. Because this GCK structure is very similar to the closed form of hexokinase I crystallized with glucose [17], it was thus identified as the closed form of the enzyme. Unlike GCK crystal structures determined with ligands, the super-open conformation is observed for the unbound GCK structure. As a result of two conformational changes compared with the closed form of GCK in this configuration, there is a much wider cleft space between the two domains of GCK due to the tilting and rotation of the small domain compared with the large domain (at an angle of 100°) in addition to extensive rearrangement of secondary structural elements within the small domain [15].Fig. 1 Surface representation of overall structure of glucokinase (GCK). The complex structure of glucose-bound GCK in the presence of the non-hydrolysable ATP analogue adenosine 50-(β,-γ-imino) triphosphate (AMP-PNP) and allosteric activator N-thiazol-2-yl-2-amino-4-fluoro5-(1-methylimidazol-2-yl)thiobenzamide (TAFMT) (PDBID: 3ID8). The complex comprises glucose (green, sphere), AMP-PNP (magenta, ball, and stick), and TAFMT (orange, sphere) with GCK in an active conformation. The conformational relationship of the large domain (light blue) and the small domain (salmon) exhibited a closed form

In the super-open conformation, GCK enzyme exhibits low glucose affinity and is catalytically inactive. During catalysis, glucose and ATP are bound at the active site in the closed conformation of GCK. The high-affinity form of the enzyme, free of substrates or products, is postulated to exist in an intermediate conformation between the super-open and closed states. As a result, this putative conformation is referred to as open [15]. GCK’s crystal structure in its open form still needs to be studied. However, an open form of hexokinase I can be modeled by X-ray diffraction studies of crystals formed in the absence of glucose [17]. Due to a slight twist of the small domain relative to the large domain, the open form displays a more comprehensive inter-domain cleft than the closed form. Compared with the complex molecular reorganization involved in the slow transition from super-open to open conformations, the transition from open to closed conformations would be extremely fast and easily reversible. The prediction of an intermediate open state for GCK has been supported by another study using targeted molecular dynamic simulations to determine when GCK transitions from a closed to a super-open state [15].

Several structures of GCK in complex with glucose and activators have been solved over the years [15, 18–23]. All the structures highlighted the same binding site for glucose and activators and validate that binding of activators does not cause conformational changes but help in stabilization of the active form of GCK. In fact, activators may help in shifting the glucose-dependent conformational equilibrium between open (inactive) GCK to closed (active) GCK as also indicated by kinetic studies [23]. These complex structures support the proposed theoretical model, where Asp105 acts as a base catalyst, Lys169 acts as an acid catalyst, and these help in the transfer of phosphoryl group between ATP and glucose during catalysis [22]. Contrarily, a slightly different model has been proposed on the basis of small-angle X-ray scattering (SAXS) in combination with crystallography studies [24]. The results suggest that GCK alternates between the active open and the active closed conformations to bind substrates and release products during the reaction cycle. These studies showed the existence of multiple conformations in solution, which may be required for efficient catalysis.

On top of the conformational switch caused by substrate/ATP/activators, GCK is also regulated by GCK regulatory protein (GKRP), where GCK interacts with GKRP through the C-terminal domain. The crystal structure of Xenopus laevis GCK in complex with GKRP was solved to establish the molecular mechanism for the allosteric regulation of GCK by GKRP [25]. The structure revealed that GKRP binds GCK in a super-open conformation, interacts mainly through hydrophobic interaction, and modulates GCK activity by restricting a small domain of GCK [25]. Allosteric effectors of GKRP, such as fructose-1-phosphate (F1P) and fructose-6-phosphate (F6P), modulate the interaction between GCK and GKRP and indirectly modify the GCK activity [25–27]. F6P destabilizes the interactions (positive), while F1P stabilizes (negative) it, reciprocally affecting GCK-GKRP complex stability. Subsequently, the crystal structure of mammalian GCK-GKRP complex in the presence of F6P (Fig. 2) was solved, showing the molecular basis of regulation of GCK by GKRP [28]. The mammalian GCK-GKRP assembly structure reveals complex regulation by sugar phosphates similar to Xenopus GCK-GKRP, where GKRP has a distant sugar phosphate binding site from the GCK interface. This cascade regulation system plays a crucial role in blood glucose homeostasis, and the interface of the GCK-GKRP complex can be a promising drug target. GKRP plays a critical role in regulating GCK activity by sequestering GCK in the nucleus when glucose levels are low and releasing it into the cytoplasm when glucose levels rise. This interaction is crucial for glucose homeostasis [29, 30]. Furthermore, the C-terminal domain contains a nuclear localization signal (NLS) that is recognized by importins, which facilitate the nuclear import of GCK-GKRP complexes. This nuclear-cytoplasmic shuttling is also central to the regulation of GCK [29].Fig. 2 Surface representation of the overall structure of GCK/GKRP complex (PDBID: 4LC9). GCK is shown in light blue (large domain) and salmon (small domain). The structure of GKRP consists of two sugar isomerase (SIS) superfamily domains and a C-terminal extended all-helical motif (CTM). GKRP is depicted in green (SIS I), wheat (SIS II), and magenta (CTM). Fructose 6-phosphate (F6P) is shown as a sphere representation and binds at the interface of SIS (I and II) and CTM

Overall, the unique structure of GCK is a crucial element of this enzyme that is intricately involved in glucose binding, regulation of enzymatic activity, and the overall control of blood glucose levels. Therefore, mutations in the GCK gene can either directly alter the enzyme’s substrate affinity or catalytic properties, leading to serious conditions such as PNDM, MODY2, and other forms of diabetes [31]. Understanding the structural and functional aspects of domains in GCK protein will be essential for unraveling the mechanisms behind glucose metabolism and diabetes-related disorders.

GCK in pancreatic β-cells

Initially, GCK expression was identified in liver and pancreatic islet tissues [5, 32]. Subsequent studies have since detected GCK expression in multiple other tissues, including pancreatic acinar, brain, lung, kidney, and spleen [3]. Early findings in the human fetal pancreatic tissue revealed that GCK is expressed at weeks 17–19 of gestation as detected through cytosolic protein extracts [33]. Another study illustrated that GCK protein expression in the human fetal pancreas starts after week 15 of gestation [34]. Consistent with these findings, recent data generated using pancreatic cells derived in vitro from human pluripotent stem cells (hPSCs) revealed that GCK is expressed primarily in the mature stages of pancreatic cells [35, 36]. The expression of GCK mRNA has been demonstrated to peak significantly during pancreatic differentiation, persisting from day 18 until the completion of differentiation at day 29 [35].

The function of GCK was first identified in pancreatic β-cells in the early 70s; the effect of glucose metabolism on the membrane electrical activity that resulted in secretion of insulin to maintain glucose homeostasis [37, 38]. GCK activity in human pancreatic islets was then described in 1985 [39, 40]. Importantly, it was disclosed that not all species have pancreatic β-cell GCK as it was found only in humans, rats, mice, and hamsters [40]. GCK in pancreatic β-cells is known to maintain glucose homeostasis by acting as a glucose sensor in the glucose metabolism pathway (Fig. 3) [4]. Subsequently, insulin is secreted from β-cells in response to high glucose levels. This acts as a key regulator of GCK activity in pancreatic β-cells [2, 41, 42], in which GCK is not inhibited by its end product, but is inhibited when the glucose level is back to normal [43]. The inflection point of the GCK-sigmoidal saturation curve with glucose is 4–8 mmol/L, which is very close to the threshold of insulin release (5 mM). As a result, when glucose level becomes close to the physiological threshold of insulin secretion, GCK activity reaches the plateau. This contributes to maintaining the fluctuating level of glucose in the blood [4, 44].Fig. 3 GCK role in pancreatic β-cells. Glucose enters pancreatic β-cells via low affinity glucose transporters. GCK then catalyzes the ATP-dependent phosphorylation of glucose into G6P. G6P starts the glycolysis and the Krebs cycle, which elevate the adenosine diphosphate (ADP) ATP/ADP ratio. Raised ATP/ADP levels result in K+ efflux, causing cell membrane depolarization and the opening of the voltage sensitive Ca2+ channels. The opening of Ca2+ channels elevate cytosolic Ca2+ levels, which, with other vital coupling factors, activate the endoplasmic reticulum and Golgi apparatus to secrete insulin granules from pancreatic β-cells

There are two different forms of GCK enzyme found in pancreatic β-cells: intrinsic high activity free-diffused form and low activity form that bind to some intracellular structures, mainly the mitochondria and insulin secretory granules [45, 46]. The binding affinity of GCK to the mitochondria may protect β-cells from apoptosis when they become intolerant to high glucose levels [47]. Therefore, this explains the importance of GCK function in minimizing the oligomerization process of Bax (the pro-apoptotic protein) and helps in the continuous release of cytochrome C from the mitochondria [47]. Separately, GCK activity is regulated and inhibited when GCK binds to insulin granules with the help of nitric oxide synthase (NOS) dimers that assist this regulation activity. However, this interaction is reversed after S-nitrosylation of the GCK enzyme, leading to the liberation of GCK from insulin granules (Fig. 4). This release of GCK will help in stimulating its activity as a post-transitional regulatory step in GCK-insulin granule interaction [8]. As a result, the localization and interaction of GCK with insulin granules are regulated by this physical interaction and chemical modulation. This GCK-bound form is a transient reservoir for its storage [8]. With the help of this association, the mobilization of cytoplasmic GCK in response to glucose change can be a rapid process when compared with the synthesis of new GCK molecules [8].Fig. 4 Regulation of GCK activity in pancreatic β-cells. In pancreatic β-cells, GCK activity is regulated by several binding partners: (1) GCK activity can be inhibited when it binds to insulin granules. The interaction between GCK and insulin granules is partly mediated by NOS. To reverse this interaction and stimulate GCK activity, NOS performs S-nitrosylation of GCK. (2) PFK-2/ FBPase-2. The regulation of GCK by PFK-2/ FBPase-2 involves direct binding of GCK and activation, depending on the phosphorylation status of FBPase-2. (3) Activation of GCK occurs via the BAD protein at the mitochondrial membrane. When phosphorylated at the BH3 domain, BAD binds to GCK near its active site, leading to GCK activation and subsequent insulin secretion. Furthermore, the interaction between BAD and GCK can provide protection against apoptosis

Phosphofructokinase-2/fructose bisphosphatase-2 (PFK-2/ FBPase-2) is a bifunctional regulatory enzyme that regulates glucose metabolism in pancreatic β-cells when bound to GCK (Fig. 4). This enhances GCK activity to regulate the intrinsic glucose level [48, 49]. Furthermore, the BH3 domain of BAD, a member of the BCL-2 pro-apoptotic protein family, binds to the GCK active site and regulates its activity [8]. BAD protein acts as a scaffold that binds and organizes different proteins, expediting the stabilization and activation of GCK and playing a crucial role in integrating the glycolysis and the apoptosis process in pancreatic β-cells through several proteins, including protein kinase A (PKA, cAMP-dependent protein kinase), protein phosphatase 1 (PP1, dual-specificity serine/threonine phosphatase), and Wiskott-Aldrich family member (WAVE1) [8]. GCK is mainly activated by the phosphorylation of BAD protein on Ser 155, resulting in stimulation of insulin release, which in turn improves the functionality and viability of β-cells [50, 51]. β-cell apoptosis, which results from inflammation or glucotoxicity, can therefore be prevented when glucose is metabolized by GCK [50, 51]. BAD also interacts with different pro-survival proteins that ultimately influence its proapoptotic function [50, 51]. The phosphorylation of BAD can result in the production of two residues, which are organized by intracellular glucose and insulin levels [8]. Importantly, it has been reported that the knockdown of BAD protein may result in a phenotype similar to that seen in the case of GCK knockdown, where it disturbs glucose-stimulated insulin secretion (GSIS) in β-cells [8].

Glucose is transported into pancreatic β-cells via low affinity glucose transporters such as glucose transporters GLUT1, GLUT2, and/or GLUT3 [2]. GLUT2 is known to be the main glucose transporter involved in glucose metabolism and is highly expressed in the liver and pancreatic β-cells in rodents [52], while GLUT1 and GLUT3 are recognized to be the main glucose transporters expressed in human islets [53]. Once glucose is transported into the cells, it gets phosphorylated into G6P with the help of the GCK enzyme. Subsequently, GCK expression reaches as high as five- to tenfold, independent of the glucose concentration [2]. Following phosphorylation, G6P undergoes glycolysis and enters the Krebs cycle, leading to increased oxidative phosphorylation in the mitochondria that generates more ATP in the cell [2]. The elevated ATP/ADP ratio in the cytosol is one of the most important coupling factors controlling insulin release [54]. When the ratio of ATP/ADP rises inside cells, K+ efflux is diminished [54]. As a result, the SUR-1/Kir6.2 KATP channel complex is inhibited, causing a depolarization of the cell membrane, and opening of the voltage sensitive Ca2+ channels. This results in an elevation of the cytosolic Ca2+ level [2]. Subsequently, insulin-containing granules will be secreted from β-cells [55]. Insulin is secreted in a biphasic manner; the first phase occurs after a few minutes of glucose stimulation, followed by a reduction of insulin release. After a few minutes of the first phase, the second phase begins, and 30–40 min after glucose stimulation, insulin secretion reaches a peak [56].

β-cell proliferation can be regulated in the presence of glucose through inducing β-cell glycolytic flux [57]. GCK expression increases when glucose levels increase, resulting in IRS-2 and cyclin D2 stimulation and upregulation, where these genes are involved in β-cell proliferation [57, 58]. IRS-2 is known to be essential in keeping the β-cell mass maintained and preventing β-cells from going under the apoptotic mechanism, which has a crucial role in preventing the occurrence of diabetes [59, 60]. Therefore, upregulation of IRS-2 via GCK activation could improve β-cell proliferation [60]. It has been shown that mice with heterozygous mutation in GCK β-cell (βGck+/−) showed an increase in ER stress and β-cell apoptosis when fed with a diet rich with linoleic acid and sucrose compared with wild type mice [61]. The use of GCK activator (GKA) increases the expression of IRS-2 and reduces CHOP and BAX protein expression, which trigger ER stress and β-cell damage. Reducing the expression of those proteins can lead to recovery of the apoptotic effect of ER stress in β-cells in prediabetic or early stages of diabetes where the β-cell damage is not massive [62, 63]. Similarly, the ubiquitin–proteasome system (UPS)—a type of posttranslational modification system—helps in regulating the activity of GCK in pancreatic β-cells [64, 65]. The UPS is involved during the synthesis and secretion of insulin after glucose induction, as well as the expression and function of ATP-sensitive K+ channels, which have an important role in maintaining glucose homeostasis in the body [64, 65]. Small ubiquitin-like modifier protein 1 (SUMO-1) is a protein that binds to GCK and contributes to the regulation of its activity by increasing its activity and stability [64, 65]. While it has been described that SUMO-conjugation binds to the closed conformational form of GCK, it is not clearly understood whether this binding causes the closed conformation form, or whether it is because of the SUMO-GCK interaction. This type of GCK regulation is considered a posttransitional modification process that contributes to the regulation of GCK function [64, 65].

At the transcriptional level, Pdx1 can regulate the transcriptional activity of the Gck promoter in the pancreatic β-cells [66]. PDX1 transcription factor is a primary regulator of pancreatic development and the differentiation of progenitors into pancreatic β-cells [67]. PDX1 regulates the expression of some islet-specific genes such as GCK [66]. A study using Chinese hamster ovary (CHO) cells showed that PDX1 expression can increase the reporter activity of the GCK promoter in pancreatic β-cells via binding on the upstream promoter element 3 (UPE3) in the GCK promoter [67]. Nevertheless, it has been shown that specific disruption of the Pdx1 gene did not influence GCK expression [68, 69].

GCK in other pancreatic islet cells

Besides the liver and pancreatic β-cells, GCK is also present in other pancreatic islet cells, such as pancreatic α- and δ-cells [70]. The endocrine part of the pancreas responds to changes in blood glucose levels by secreting hormones, either glucagon from α-cells in a fasting state or insulin from β-cells after or during meals [71, 72]. The liver responds to glucagon secretion by mobilizing glucose from its intracellular glycogen storage, while the secretion of insulin results in increased uptake of glucose from the portal vein [72]. Therefore, this system is regulated by glucose and has positive feedback on insulin secretion [71] but negative feedback on glucagon secretion [73].

In α-cells, glucose requires GCK to suppress the expression of glucagon that is released to prevent hypoglycemia, especially during hyperglycemia. The general properties of GCK in α-cells are similar to that of GCK in β-cells in terms of saturation (high S0.5) and non-inhibition property by its end product G6P [74]. Although the glycolysis process in α-cells and β-cells is similar, the ATP produced is less in α-cells because the oxidative phosphorylation efficiency resulting from high expression of uncoupling protein 2 is lower [75, 76]. The knockdown of GCK affects the regulation of glucagon secretion [77], as is evidenced from mice with inactivated GCK in α-cells [78]. Due to the absence of GLUT2 transporter in pancreatic α-cells, intracellular glucose level is maintained between 1/2 and 2/3 of serum level. This range is sufficient for GCK to serve as a glucose sensor in these cells [79].

The sorting of pancreatic α-cells from rat islets revealed that GCK stands as the sole hexokinase enzyme detected within the determined limit [77]. This finding underscores the minimal expression of hexokinase I, as validated in earlier studies on α-cells [78]. The presence of GCK in α-cells has also been noticed in enriched islets of rats treated with streptozotocin [70]. Moreover, abnormalities in GCK gene expression have been noted to disrupt insulin release triggered by glucose induction and impair the release of glucagon through glucose suppression [80]. This particular defect has been observed in certain instances of MODY2 within families harboring congenital mutations in the GCK gene [81].

Studies conducted on MODY2 patients with GCK heterozygous mutation showed increased glucagon secretion from α-cells during the hyperinsulinemic/hypoglycemic clamps, which are stimulated at high glucose concentrations. However, the reason is unclear: is it because of the direct consequence of GCK defects in α-cells, or is it influenced by glucose-sensing neurons in the central nervous system [82]. To elucidate the critical role of GCK in α-cell glucose sensing, mice with α-cell-specific Gck deletion have been generated. Published data underscore the importance of the intrinsic regulation of α-cells [78]. Inactivation of Gck in α-cells disrupt the ATP/ADP ratio and the KATP channel closure in α-cells, leading to hyperglucagonemia in the fed state and an increment in glucose produced by the liver [78]. Furthermore, glucagon secretion is suppressed in Gck-deficient α-cells, even in the presence of other extrinsic regulatory factors such as paracrine, hormonal, and neuronal control. This collective evidence underscores the importance of intrinsic regulation of GCK within the α-cell for glucagon secretion [78]. Moreover, abnormal suppression of glucagon will affect hepatic glucose metabolism, resulting in the induction of prediabetic conditions [78].

In addition, it has been reported that the pancreatic polypeptide cells (PP) cells do express GCK at a low level, while other hexokinases are not expressed [77].

GCK in liver

The regulation of blood glucose levels by the liver is more complex than that of pancreatic islets. By converting glucose to G6P, GCK enhances glycogen synthesis and contributes to removing glucose from the portal vein [83]. The liver also plays an essential role in endogenous glucose production to maintain normal glucose levels during fasting [84]. Therefore, GCK activity is required for efficient glucose clearance after a meal, whereas it should be inactive during fasting to prevent glucose conversion to G6P [14, 84]. In the liver, GCK expression is strictly driven by the presence of insulin. It is abolished in the liver of insulin-deficient rats [1, 85]. The induction of GCK expression by insulin has been shown to occur at the transcriptional level, where insulin triggers around a 15-to-30-fold increase in Gck mRNA independently of glucose [86]. In addition to the transcriptional induction of GCK gene expression, GCK is also subject to several protein–protein interactions that produce a wide range of physiological consequences. The liver’s earliest and best-characterized partner of GCK is glucokinase regulatory protein (GKRP) [87, 88]. GKRP is a 65 kDa monomeric enzyme primarily localized in the liver nucleus [83, 89]. GKRP has also been detected in the cytosol and mitochondria complex with GCK [90]. Since GKRP was discovered more than 30 years ago, it has been extensively studied using various biochemical, biophysical, and structural methods. Structural analysis revealed that GKRP binds the super-open conformation of GCK mainly through a hydrophobic interaction [25]. This binding makes GKRP a competitive inhibitor of glucose association with the enzyme [25]. Furthermore, GKRP binding to GCK sequesters the complex in the nucleus of hepatocytes [89]. The exact mechanism by which GKRP mediates GCK nuclear translocation remains unclear. A possible mechanism is via a signaling sequence. Importantly, this mechanism was identified in the pancreatic GCK in a region of the enzyme that is also conserved in the liver isoform [91].

GKRP-mediated GCK regulation is subject to further modulations. For example, phosphorylated carbohydrates such as fructose-6-phosphate (F6P) enhance the interaction between GKRP and GCK [92]. The analysis of GKRP association with a fluorescent variant of human GCK revealed that GKRP binding to GCK is a two-step process. The first step is forming an initial encounter complex, while the second step is the conformational equilibrium between two GKRP-GCK states [93]. This analysis described that F6P enhances GKRP-GCK interaction by promoting the formation of the initial encounter complex. Another modulator of GKRP is fructose 1-phosphate (F1P) [25]. In contrast to F6P, F1P weakens GKRP-GCK interaction by altering the hydrophobic interaction between GCK and GKRP [25].

Posttranslational (PT) processes have also been shown to modulate liver GKRP–GCK interaction. For example, GCK SUMOylation stabilizes and activates GCK [8, 91]. However, SUMOylation of GCK impairs GKRP’s capacity to promote the nuclear translocation of GCK [8, 91]. Moreover, the attachment of one or more SUMO proteins to GCK at Lys12, Lys13, Lys15, and Lys346 may conceal the NES (nuclear export signal), preventing the nuclear export of GCK while it is SUMOylated [8, 91]. Another PT event is the acetylation of GKRP near the N-terminus by P300 acetyltransferase. This prolongs GKRP lifespan and increases its inhibitory effects [94]. The presence of several mechanisms regulating GKRP–GCK interaction highlights the physiological importance of regulating GCK activity in the liver.

Genetic variants of GCK in monogenic diabetes

Mutations in the GCK gene can result in various forms of diabetes. These mutations can either directly alter the enzyme’s substrate affinity or catalytic properties, leading to severe conditions such as MODY2 and other forms of diabetes [31]. More than 600 GCK mutations have been reported to cause different monogenic glycemic disorders (Table 1) [9]. Therefore, studying the defects in GCK expression in the liver, pancreas, or both has a vital role in understanding the cause of monogenic diabetes [95]. Several studies explained how the reduction in the activity of GCK in pancreatic β-cells in transgenic mice resulted in insulin secretion reduction in response to glucose while showing no significant change in fasting plasma glucose level or glucose tolerance [1, 96]. Those studies could confirm the contributive role of global GCK defect (pancreatic and hepatic GCK) in developing MODY2 disease [1, 96]. There are three types of mutations identified in the GCK gene: (i) missense mutations that affect the sequence of the GCK gene and prevent the normal conformational changes; (ii) nonsense mutations that result in the generation of truncated molecular form of GCK; and (iii) deletion and splicing mutation(s) that may result in the synthesis of defective mRNA that cannot translate to normal and functional protein [97].Table 1 Examples of the most common mutations in the GCK gene

	Mutation point	Region	Protein change	References	
MODY2	
 1	c.-71G>C	Islet promoter	NA	[121]	
 2	c.106C>T	Exon 2	p.Arg36Trp	[136]	
 3	c.157G>T	Exon 2	p.Ala53Ser	[130, 136]	
 4	c.175C>T	Exon 2	p.Pro59Ser	[137]	
 5	c.182A>G	Exon 2	p.Try61Cys	
 6	c.184G>A	Exon 2	p.Val62Met	[133, 134]	
 7	c.208G>A	Exon 2	p.Glu70Lys	[130, 132, 138]	
 8	c.214G>A	Exon 3	p.Gly72Arg	[133, 139]	
 9	c.234C>G	Exon 3	p.Asp78Glu	[137]	
 10	c.239G>C	Exon 3	p.Gly80Ala	[130, 136]	
 11	c.260T>C	Exon 3	p.Val86Ala	[140]	
 12	c.349G>A	Exon 3	p.Gly117Ser	
 13	Deletion in the 5ʹ splice site of intron 4	intron 4	NA	[120]	
 14	Deletion of the T of the GT in the splice donor site of intron 4 and the following 14 base pairs	Intron and exon 4	K161 + 2de115	[98]	
 15	c.401C>T	Exon 4	p.Leu134Pro	[141]	
 16	c.410A>G	Exon 4	p.His137Arg	[130]	
 17	c.413A>C	Exon 4	p.Gln138Pro	[141]	
 18	c.437T>G	Exon 4	p.Leu146Arg	[139]	
 19	c.451_453delTCC	Exon 4	p.Ser151del	[142]	
 20	c.457 C>T	Exon 4	p.Pro153Ser	[141]	
 21	c.469G>A	Exon 4	p.Glu157Lys	
 22	c.475A>G	Exon 4	p.Ile159Val	[140]	
 23	c.478G>C	Exon 4	p.Asp160His	
 24	c.480_482dupTAA	Exon 4	p.Asp160_Lys161 insAsn	[109]	
 25	c.493C>T	Exon 5	p.Leu165Phe	[143]	
 26	c.502A>C	Exon 5	p.Thr168Pro	[130, 136]	
 27	c.505 A>G	Exon 5	p.Lys169Glu	[141]	
 28	c.512T>C	Exon 5	p.Phe171Ser	[140]	
 29	c.524G>A	Exon 5	p.Gly175Glu	[130]	
 30	c.544G>T	Exon 5	p.Val182Leu	[144]	
 31	c.544G>A	Exon 5	p.Val182Met	[145]	
 32	c.544G>A	Exon 5	Val182Met	[98, 145]	
 33	c.556C>T	Exon 5	Arg186 to stop	
 34	c.562G>A	Exon 5	p.Ala188Thr	[101]	
 35	c.579 G>T	Exon 5	p.Gly193Gly	[141]	
 36	c. 595 G>A	Exon 6	p.Val199Met	
 37	c.608T>C	Exon 6	p.Val203Ala	[98, 130, 132, 145]	
 38	c.617C>T	Exon 6	p.Thr206Met	[143]	
 39	c.622G>A	Exon 6	p.Ala208Thr	[139]	
 40	c.626C>T	Exon 6	p.Thr209Met	[136]	
 41	c.629T>C	Exon 6	p.Met210Thr	[130]	
 42	c.637T>C	Exon 6	p.Cys213Arg	[130, 136, 146]	
 43	c.676G>A	Exon 6	p.Val226Met	[130, 136]	
 44	c.697T>C	Exon 6	p.Cys233Arg	[144]	
 45	c.703A>G	Exon 6	p.Met235Val	[109]	
 46	c.755G>A	Exon 6	p.Cys252Tyr	[146]	
 47	c.766G4A	Exon 6	p.Glu256lys	[98]	
 48	c.769T>C	Exon 6	p.Trp257Arg	[101]	
 49	c.781G>A	Exon 6	Gly261Arg	[98, 100, 130]	
 50	c.787T>C	Exon 6	p.Ser263Pro	[139]	
 51	c.793G>A	Exon 6	p.Glu265Lys	[143, 144]	
 52	c.835G>C	Exon 6	p.Glu279Gln	[98]	
 53	c.713T>C	Exon 7	p.Met238Thr	[140]	
 54	c.819T>G	Exon 7	P.Tyr273X	
 55	c.841T>G	Exon 7	p.Ser281Ala	
 56	c.895G>C	Exon 8	Gly299Arg	[98, 147]	
 57	c.898G>C	Exon 8	Glu300Gln	[98]	
 58	c.898G>A	Exon 8	p.Glu300Lys	[98, 130, 132]	
 59	c.922A>T	Exon 8	p.Arg308Trp	[109]	
 60	c.926T>C	Exon 8	p.Leu309Pro	[98, 130]	
 61	c.944T>C	Exon 8	p.Leu315Pro	[141]	
 62	c.950A>C	Exon 8	p.His317Pro	[140]	
 63	c.1007C>T	Exon 8	p.Ser336Leu	[130, 148]	
 64	c.1016A>G	Exon 8	p.Glu339Gly	[139]	
 65	c.1055T>C	Exon 8	p.Leu352Pro	[140]	
 66	Splicing mutation: mutation of the splice acceptor site in intron9 from AG to AC	Intron 9 and exon 10	S418-1G to C	[145]	
 67	c.1030G>T	Exon 9	p.Asp344Tyr	[149]	
 68	c.1099G>A	Exon 9	p.Val367Met	[130, 136]	
 69	c.1121_1132del12	Exon 9	p.Val374_Ala377del	[142]	
 70	c.1129C>T	Exon 9	p.Arg377Cys	[139]	
 71	c.1136C>T	Exon 9	p.Ala379Val	[144]	
 72	c.1229G>T	Exon 9	p.Gly410Va	[141]	
 73	c.1240A>G	Exon 9	p.Lys414Glu	[128, 130]	
 74	c.1222G>T	Exon 10	p.Val408Leu	[140]	
 75	c.1256T>G	Exon 10	p.Phe419Cys	
 76	c.1258A>G	Exon 10	p.Lys420Glu	[144]	
 77	c.1322 C>T	Exon 10	p.Ser441Leu	[141]	
 78	c.1358C>T	Exon 10	p.Ser453Leu	[139]	
MODY2-PNDM	
 79	c.437T>C	Exon 4	p.Leu146Pro	[150]	
 80	c.502A>G	Exon 5	p.Thr168Ala	[151]	
 81	c.629T>A	Exon 6	p.Met210Lys	[139]	
 82	c.790G>A	Exon 6	p.Gly264Ser	[107, 139]	
 83	c.1133C>T	Exon 9	p. Ala378Val	[107]	
 84	c.1190G>T	Exon 9	p.Arg397Leu	[109]	
HH	
 85	c.191C>A	Exon 2	p.Ser64Tyr	[152]	
 86	c.194C>T	Exon 2	p.Thr65Ile	[125, 135]	
 87	c.203G>T	Exon 2	p.Gly68Val	[153]	
 88	c.295T>A	Exon 3	p.Trp99Arg	[125, 135, 146]	
 89	c.296G>T	Exon 3	p.Trp99Leu	[123]	
 90	c.591G>T	Exon 6	p.Met197Ile	[123]	
 91	c.641A>G	Exon 6	p.Tyr214Cys	[129, 135, 154]	
 92	c.1361_1363dupCGG	Exon 10	p.Ala454dup	[123]	
 93	c.1363C>A	Exon 10	p.Val455Met	[124, 130, 132]	
 94	c.1367C>T	Exon 10	p.Ala456Val	[126, 128, 129, 135]	

GCK mutations have been identified across exons 2–10, with a notable concentration observed in exons 5–8 [98]. Exon 5 is particularly significant as it encodes the region responsible for inducing the enzyme’s conformational change upon glucose binding, leading to the closure of the active site cleft [99]. Exons 6–8 encode residues crucial for both the active site and its cleft [100, 101]. Therefore, research efforts have focused on studying mutations within these exons [102, 103] and some investigations into mutations reported in exon 1 [103]. Routine sequencing checks have also uncovered numerous cases of polymorphisms in the GCK gene, with the IVS9+8T>C variant being the most commonly identified polymorphism [103].

PNDM

PNDM, a rare and severe form of monogenic diabetes, typically emerges within the first 6 months of life [104]. Generally, these patients have first-degree relatives with reported glucose intolerance. Patients with PNDM require a lifelong insulin treatment supply that is usually accompanied by sulfonylurea [105]. This condition arises from autosomal recessive mutations, either due to homozygous mutations or compound heterozygosity involving nonsense, frameshift, or missense mutations, leading to complete loss of GCK function [7, 106, 107]. The first discovery of PNDM caused by GCK mutations was documented in 2001, with two reported cases from Norway and Italy [7]. An example of homozygous inactivating mutation causing PNDM is Ala378Val (A378V). This missense mutation, located near the GCK active site, disrupts the binding ability of GCK with glucose [107]. There are other types of homozygous mutations that present in splice donor sites and can result in forming an inactive GCK protein [107]. PNDM can also result from compound heterozygous mutations, such as (G264S/IVS8+2T G), where one allele has a mutation in the splice site in one exon (IVS8+2T→G) and the other allele has a missense mutation such as Gly264Ser [107]. Although the Gly264Ser missense mutation exhibits normal enzymatic activity, the exact cause of the disease is not fully understood. Nonetheless, severe PNDM has been observed in patients harboring such mutations [107]. Another rare example of homozygous mutation within the GCK gene linked to PNDM is the Gly223Ser mutation. This mutation occurs within the β-sheet, particularly the hydrophobic core in the large domain of GCK [108]. In this mutation, there is a substitution of glycine to serine, which affects the activity and structure of GCK [109]. Consequently, patients with this mutation develop severe hyperglycemia and ketoacidosis symptoms due to the complete loss of GCK, aligning with the PNDM phenotype [108]. Up to date, most PNDM due to GCK homozygous mutations has been diagnosed during infancy. However, there have been some rare cases of GCK homozygous mutations diagnosed outside infancy. For example, Raimondo et al. reported the first two cases of PNDM diagnosed at 9 and 15 years of age, with mutations c.478G>A (p.D160N) and c.676G>A, (p.V226M), respectively [110].

MODY2

Heterozygous mutation in the GCK gene is known to cause MODY2, characterized by mild fasting hyperglycemia. In MODY2, GCK gene shows functional defects reported in approximately 1 out of 1000 of the population [111]. The clinical similarities between MODY2 and other diabetes types can complicate diagnosis, often resulting in misdiagnosis and inappropriate treatment with insulin or oral hypoglycemic agents. Patients typically do not require pharmacological intervention, and their risk of diabetes-related vascular complications is relatively low [111–113]. The discovery of GCK mutations as the genetic cause of MODY2 first occurred in 1992 groups [6, 114]. Compared with individuals diagnosed with transcription factor MODY who develop diabetes during young adulthood or adolescence and advance to marked hyperglycemia, accompanied by escalating treatment needs and an increased risk of diabetes-related complications, MODY2 only results in mild hyperglycemia. This unique pathophysiology observed in individuals with MODY2 emphasize the importance of considering them as a separate genetic subgroup, markedly divergent from other MODY subtypes [115].

Heterozygous mutations in GCK present in two forms: loss-of-function (MODY2) or gain-of-function (GCK-hyperinsulinaemic hypoglycemia, GCK-HH). Loss-of-function mutations in GCK lead to defective glucose sensing mechanism in pancreatic β-cells, resulting in reduced insulin secretion due to an increased glucose threshold needed for insulin release. Consequently, this leads to elevated fasting glucose levels and the development of MODY2 diabetes [111, 116]. Furthermore, patients with MODY2 exhibit decreased glycogen production in the liver in response to reduced insulin release, along with increased hepatic glucose production (gluconeogenesis) post-meals [117]. This contributes to the hyperglycemic conditions in MODY2, supported by studies that showed reduced glucose cycling in the liver and abnormally high endogenous glucose production relative to plasma glucose concentration in affected individuals [117, 118]. Notably, elevated fasting glucose levels in MODY2 do not correlate with body mass index (BMI), as this is observed to a similar degree in slim and obese people [119].

Some mutations in the intronic region of the GCK gene can cause MODY2 with hyperglycemia symptoms. These mutations can result in the deletion of entire exons or the formation of abnormal transcripts. For example, the deletion of 15 base pairs in the donor splice site of intron 4, where the “T” of the “GT” is removed with the subsequent 14 base pairs, leads to the formation of two defective transcripts; one transcript lacks the entire exon 5, while the other is missing the last eight codons of exon 4 [120]. Deletion mutations in the intronic region, particularly in the donor splice site, have been demonstrated to cause a severe form of glucose intolerance compared with the form resulting from the GCK point mutations, as they have a more detrimental effect on insulin secretion [120].

Mutations in promoter regions of important β-cell genes can also cause the phenotype observed in certain cases of MODY2, even in the absence of mutations within the exons or introns of the GCK gene [121]. Studies have revealed mutations such as −71G>C, which are detected during sequencing of the GCK promoter region. This mutation occurs in a non-conserved region of the human GCK promoter, leading to a defect in promotor activity of up to fourfold [121]. This finding underscores the vital role of non-coding regions in developing diseases such as MODY2 and emphasizes the necessity of including these regions in disease screening protocols [121].

GCK-HH

GCK hyperinsulinism (GCK-HI) constitutes a rare congenital form of HI. Mutations associated with GCK-HI induce an increase in GCK enzymatic activity, leading to a lowered glucose threshold for glucose-stimulated insulin secretion (GSIS) in pancreatic β-cells [122]. In 1998, hyperinsulinaemic hypoglycemia due to heterozygous gain-of-function mutation (GCK-HH) was identified [111, 123, 124]. This mutation increases the affinity of GCK for glucose, resulting in a lower threshold for insulin release [42]. Consequently, previous studies reported symptoms of stable and persistent hypoglycemia correlated with increased insulin release. This increased insulin secretion is observed in response to intravenous stimulation of glucose, resulting in hyperinsulinemia [42]. The spectrum of hyperinsulinism ranges from mild to intermediate to severe forms. Treatment approaches depend on the severity of each case; for example, diazoxide is usually used for intermediate cases, while more severe instances may necessitate pancreatectomy to manage the hypoglycemic condition [123]. In addition, it has been reported that there are over 11 activating GCK mutations, with the majority located in the allosteric region of GCK where the GCK activators bind [125, 126].

It has been reported that the Val455Met mutation, located in exon 10 of the GCK gene, is a conservative missense mutation linked to GCK-HH, despite the fact that this mutation is not present in the GCK–glucose binding site and there being no familiar missense mutations associated with MODY2 in that region [124]. Hence, many kinetic analyses have been performed to elucidate this association. Interestingly, analyses demonstrated that the Val455Met mutation enhances the affinity of GCK for glucose, resulting in an increased glycolysis rate at low concentrations of glucose and elevated insulin secretion at lower plasma concentrations. This could explain the hypoglycemia and hyperinsulinemia observed in families carrying this mutation [124].

Most GCK-HH mutations occur within the enzyme’s active site, impacting its catalytic activity through disturbing its binding with glucose [127]. Furthermore, other mutations located in different sites, such as promoter regions, may influence the expression of tissue-specific GCK in hepatic or pancreatic β-cell splicing sites, GCK regulatory domains such as the fructose 6-/fructose 1-phosphate regulatory protein binding site, and GCK regulatory sites [127]. A study used mice with specific genetic backgrounds to understand the association between missense mutations in GCK and glycemic disease [128]. These mice have been engineered to carry either activating mutations, such as Ala456Val [129], or inactivating mutations, such as Lys414Glu [130], in the Gck gene. Results revealed that mice heterozygous for the inactivating mutation (Lys414Glu) displayed hyperglycemia, representing the phenotype of MODY2, while mice with the heterozygous activating mutation (Ala456Val) showed hypoglycemia, characteristic of GCK-HH [128]. Consequently, the threshold for GSIS from pancreatic β-cells has been changed depending on the mutation type, either activating or inactivating; mice with activating mutations showed elevated plasma insulin concentrations, whereas those with inactivating mutations exhibited slightly lower levels [128]. Nevertheless, some reported mutations, such as S263P and G264S, may be catalytically normal, but if overexpressed in certain cells such as HEK293 cells and MIN6 β-cells, they will lead to the generation of misfolded proteins that result in destabilization and/or cellular dimerization/aggregation with an accelerated rate of degradation [131].

Moreover, hepatic GCK activity has been found to be affected in mice with activating mutation, resulting in a significant downregulation of GCK protein levels in the liver [128]. Such observation could be explained by the mutation causing the translation of the unstable GCK protein [132]. Another explanation is that there may be disruption in the interaction between GCK and its regulatory protein (GKRP) [128].

Taken together, mutations in GCK causing MODY2 not only affect the kinetics of the enzyme, but also impair its stability [131, 132], its interaction with other regulatory proteins such as GKRP [133, 134], and its ability to bind with other bifunctional enzymes such as PFK-2/FBPase-2 [133], or binding with some activators in the allosteric site [134]. Furthermore, mutations causing GCK-HH to impair various enzymatic mechanisms, including increasing the GCK–glucose binding affinity and other mutations, help to change the GCK form into its active form [135].

GCK variants linked to type 2 diabetes (T2D)

It has been reported that a high proportion of patients with T2D carry some rare GCK variants. Depending on the type of GCK variant, these patients can have a glycemic phenotype and a treatment response consistent with known GCK monogenic diabetes [155]. For example, patients with T2D with known pathogenic GCK variants such as c.214G>A and c.659G> often display lower fasting glucose and C-peptide levels similar to MODY2. In contrast, those with benign variants such as c.1024A>C typically exhibit distinct glycemic phenotypes characterized by higher fasting glucose and c-peptide levels T2D [156]. Moreover, it has been investigated that some common variant in the GCK gene with a minor allele frequency of ≥ 0.01 is linked with T2D and some metabolic traits. A novel 3′ untranslated region (3′UTR) SNP, in chr7:44184184-G/A, has been found to be associated with the post-absorptive carbohydrate oxidation rate and during a hyperinsulinemic–euglycemic clamp, as well as its association with T2D. Such variants in the GCK gene could influence the carbohydrate oxidation rate and are reported to be associated with T2D [156]. The GCK rs1799884 variant has been identified as another example of a GCK variant associated with T2D, specifically in Caucasians [157] and Malaysians [158]. This association has been established by studying the genotypic and allelic frequencies of this variant in combination with variants in GCKR (rs780094), and G6PC2 (rs560887), revealing significant differences in patients with T2D and controls and highlighting the combined impact of these variants on T2D risk [158]. The presence of these alleles results in an elevation in the insulin secretion set point, disrupting physiological glucose homeostasis and resulting in increased FPG levels according to the number of available risk alleles, thereby increasing susceptibility to T2D [159].

Furthermore, another study showed a negative association between FPG and expression of GCK in patients with T2D, which indicates that activation of GCK could be essential for β-cell adaptation and proper glycemic control. Those results are consistent with hepatic GCK in patients with T2D, confirming the negative correlation between the GCK and FPG [160]. In addition to the previously highlighted variants, another SNP rs13306393 has been observed at a higher frequency in patients with T2D within a Chinese population [161]. Interestingly, this SNP is located at the intron near the liver-specific promoter (exon 1b). Therefore, it is exclusively expressed in the liver GCK. Evaluation of such variant showed that the increased risk of T2D is due to insulin resistance rather than impairments in the islet β cell biology [162]. This was the first study to show that GCK variants increase insulin resistance. The association between T2D and SNPs, including GCK rs1799884 G>A, MIR-196A-2 rs11614913 C>T, and MIR-423 rs6505162, have been investigated in a Saudi population. The study revealed a significant association of the AA genotype and A allele of GCK rs1799884 G>A with T2D susceptibility, alongside an association of the MIR-196A-2 rs11614913 CT genotype and T allele, as well as the MIR-423 rs6505162 CA genotype, with T2D [163].

Overall, these findings underscore the impact of GCK variants on T2D phenotypes and highlight the importance of genetic factors in disease susceptibility and treatment response. Additionally, they provide valuable insights for future research endeavors aimed at elucidating the intricate genetic architecture of diabetes and enabling personalized therapeutic strategies.

Modeling GCK-associated monogenic diabetes: insights from animal and cell models

In light of GCK’s involvement in various forms of MD, animal models have been established to study the role of GCK in developing hyperglycemia and hypoglycemia (Table 2) [96, 117, 155, 164]. Early studies attempted to generate homozygous global Gck knockout (KO) mice to mimic the phenotypes of PNDM [96, 164]. However, these studies were unsuccessful in producing mice that completely lack Gck, as its absence has been shown to be lethal during development [96, 164].Table 2 Gck knockout mouse models

KO models	Clinical phenotypes	References	
Gck KO mouse models	Embryos die at day 9.5	[96]	
Mice develop hyperglycemia after the second day of birth and die within the first week	[155, 164]	
Mouse survive for 5 weeks after birth	[155]	
KO model of pancreatic GCK	Die a few days after birth due to severe diabetes	[117]	
KO model of hepatic GCK	Mild hyperglycemia with defect in the synthesis of glycogen	[117]	
Heterozygous deficiency of global or pancreatic GCK	Moderate hyperglycemia	[117, 164]	
Heterozygous deficiency of hepatic GCK	In the liver, decrease in the mRNA level of insulin receptor and Glut2 expression

In the pancreas, there is a large amount of glucagon secreted from α-cells

In muscles, hexokinase II (HKII) is decreased while there is no obvious change in adipocyte tissue

	[52]	

Nevertheless, some studies employed N-ethyl-N-nitrosourea (ENU)-induced mutagenesis strategy to generate Gck mutant mice through the induction of specific point mutations [155, 156]. These studies successfully generated mice with homozygous GCK mutations [155, 156]. The use of ENU-induced mutations revealed that different types of homozygous GCK mutations result in different phenotypes. For example, mice with a splicing donor mutation in the β-cell exon 1 (M-210) suffer marked hyperglycemia and severe growth retardation, leading to death within the first week after birth [155]. In contrast, mice with the missense mutation Va1182Met (M-392) survive up to 5 weeks after birth despite having a functionally impaired GCK protein [155]. Taking all together, these findings highlight the importance of GCK during development and underscore that the severity of phenotype depends on the type of homozygous GCK mutation.

To elucidate the role of GCK in specific tissues, β-cell and liver-specific Gck KO models have been generated through Cre-LoxP gene-targeting technology [165]. Mice lacking β-cell specific Gck exhibit severe hyperglycemia and die shortly after birth [165]. This β-cell-specific Gck KO mouse model is similar to mutant mice generated by Terauchi et al., which lack the expression of the neuroendocrine isoform of Gck in all sites, including islets, brain, and gut [166]. The similarity between these two distinct models indicates that the phenotype observed in the neuroendocrine isoform Gck KO is mainly due to the loss of β-cell specific GCK, highlighting its essential role in glucose homeostasis [165, 166].

In contrast to β-cell specific Gck KO, liver-specific Gck KO mice survived. However, in vivo, analysis of mice with liver-specific Gck KO showed marked impairment in glycogen synthesis and unexpectedly in insulin secretion [165]. To further characterize the role of liver-specific GCK in glucose homeostasis, Zhang and his colleagues generated a mouse model that lacked liver-specific GCK. The later mouse model showed a decrease in the levels of Gck protein and activity with age [159]. At the age of 6 weeks, impaired glucose tolerance and elevated fasting glucose levels are observed [159]. Importantly, this phenotype is independent of the pancreatic β-cells, as the function of β-cell Gck is normal in mice at a young age [159]. These results highlight the importance of liver GCK in maintaining glucose homeostasis and present an ideal animal model to study the pathogenesis of MODY2 [159].

In addition to homozygous Gck KO mice, global and β-cell-specific heterozygous Gck mutant mice have been generated. Both types of heterozygous Gck mutants showed a hyperglycemic phenotype and a defective insulin secretion in response to glucose. In vivo analysis of mice with global heterozygous Gck mutation showed a marked glucose intolerance during hyperglycemic clamp studies [165]. This glucose intolerance phenotype was similar to a previously reported mouse model generated by Bali et al., which also showed glucose intolerance in adult mice with a single functional GCK gene copy [96, 165]. Importantly, these studies confirmed that GCK haploinsufficiency impaired insulin secretion and provided a relevant model for MODY2.

Different research groups have also developed transgenic mice overexpressing the Gck gene. Several studies showed that mice with increased expression of pancreatic and liver-specific Gck showed an increase in hepatic glucose metabolism and a reduction in the levels of plasma glucose levels [160, 167]. Similar findings were observed following the overexpression of GCK in the livers of both fasted and fed rats, as well as in diabetic mouse models. Collectively, these studies displaying increased liver Gck expression and reduced plasma glucose levels, suggested a promising therapeutic avenue for diabetes treatment following GCK overexpression [162, 163]. However, they also observed adverse effects of Gck overexpression, such as altered lipid metabolism with elevated serum triglyceride levels [162]. To assess the long-term impacts of hepatic Gck overexpression, Ferre et al. produced transgenic mice overexpressing Gck in the liver through the PEPCK promoter at 12 months of age [168]. Their findings indicate that prolonged Gck overexpression leads to increased hepatic lipogenesis and circulating lipid levels, potentially contributing to an insulin-resistant phenotype and diabetes onset in these mice [168]. These results, along with previous reports, raise concerns regarding GCK manipulation due to its adverse effects on lipid metabolism.

Recently, Chen et al. generated a unique mouse model, as it manipulated the Gck activity in a small population of β-cells through the use of the αGSU-Cre transgene, which is active in a small subset of islet β-cells [169]. To induce Gck deletion in a subset of β-cells, the αGSU-Cre mouse has been crossed with Gck floxed conditional mouse, previously characterized by Postic et al. [165, 169]. Conversely, to activate Gck in a small subset of β-cells, the αGSU-Cre mouse has been crossed with GCK mutant mouse harboring ins454A activating mutation [169, 170]. Characterization of the generated mice showed that genetically activated GCK in a subset of β-cells is efficient in changing the glucose threshold for insulin secretion, and hence, the glucose homeostasis in the whole animal [169]. On the contrary, GCK inactivation in a minority of β-cells has no effect on glucose homeostasis. These results suggest that increased activity of GCK in a minority of β-cells directs them to function as a regulatory trigger for insulin secretion across the entire islet structure [169].

Overall, the use of animal models has contributed significantly to understanding the role of GCK in glucose homeostasis. However, it is important to acknowledge that these models do not entirely mimic all human pancreas development and diabetes pathogenesis due to inherent variances in physiology and metabolism [53, 171, 172]. Therefore, there is a need for robust preclinical models to study the molecular mechanisms of GCK mutations/variants. Leveraging advancements in hPSC technology, researchers have strived to develop more reliable models. These hPSCs, including human embryonic stem cells (hESCs) and human-induced PSC (hiPSCs) can differentiate into all cell types. Importantly, hPSCs generate patient-specific cells, thereby recapitulating the genetic signature of the patients with diabetes (reviewed in [173–175]). Moreover, stem-cell-based models have demonstrated their efficacy in serving as a powerful tool for modeling CHI [176]. More recently, multiple hiPSC lines have been successfully generated from patients with MODY2 and PNDM due to heterozygous and homozygous mutations in the GCK gene, respectively (c.437 T>C) [150]. These models offer promising avenues for studying GCK mutations and developing targeted therapies (Fig. 5).Fig. 5 Schematic representation of the hPSC-based approaches for modeling monogenic diabetes caused by GCK mutations. Modeling monogenic diabetes (MD) caused by GCK mutations can be achieved by utilizing human pluripotent stem cells (hPSCs). One approach entails introducing GCK mutations or knocking out the GCK gene using gene editing tools on preexisting hPSC lines (1). Alternatively, induced pluripotent stem cells (iPSCs) can be generated from patients with GCK mutations (patient-iPSCs), followed by correcting the mutation using genome editing tools (2). These hPSC lines can then be differentiated into β-cells and liver cells to study the impact of the mutation or edited gene on the development and function of the β-cells and liver cells

Conclusions and future perspectives

The pivotal role of GCK in glucose metabolism, particularly in pancreatic islets and the liver, underscores its significance in maintaining blood glucose homeostasis. Structural and functional insights into GCK have elucidated its unique characteristics and regulatory mechanisms, providing a foundation for understanding its contribution to diabetes pathogenesis. Mutations and variants in the GCK gene are associated with various monogenic and polygenic forms of diabetes, emphasizing the need for robust preclinical models to study disease mechanisms accurately. Animal models have offered valuable insights into GCK-related diabetes, but limitations remain in fully replicating human phenotypes. Recent advancements in hPSC technology show promise in overcoming these challenges, offering patient-specific iPSC and gene-edited hPSC models to unravel the molecular underpinnings of GCK-linked diseases. Moving forward, integrating insights from structural biology, genetic studies, and disease modeling will deepen our understanding of GCK-associated diabetes and pave the way for targeted therapeutic interventions.

Abbreviations

G6P Glucose-6-phosphate

GCK-HI Glucokinase hyperinsulinism

GCK Glucokinase

GKRP GCK regulatory protein

GSIS Glucose-stimulated insulin secretion

HH Hyperinsulinemic hypoglycemia

hPSCs Human pluripotent stem cells

iPSCs Induced pluripotent stem cells

MD Monogenic diabetes

MODY2 Maturity onset diabetes of the young 2

NOS Nitric oxide synthase

PNDM Permanent neonatal diabetes mellitus

T2D Type 2 diabetes

UPS Ubiquitin–proteasome system

Acknowledgements

We would like to thank Dr. Racha Chouaib (QBRI, HBKU) for reading the early version of this review.

Author contributions

Y.A. and A.A. contributed to the data collection and writing the original draft of the manuscript. I.I.A. contributed to review and editing of the manuscript. Z.I. and P.R.K. contributed to writing and editing the structural biology section of the manuscript. A.K.K.T. contributed to the review and editing of the manuscript. E.M.A. contributed to the conception, design, and review and editing of the manuscript. All authors read and approved the final version of the manuscript.

Funding

This work was supported by a budget from Sidra Medicine (SDR400216). A.K.K.T. is supported by IMCB, A*STAR, HLTRP/2022/NUS-IMCB-02, OFIRG21jun-0097, CSASI21jun-0006, MTCIRG21-0071, H22G0a0005, I22D1AG053, HLCA23Feb-0031, and SC36/19–000801-A044.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

A.K.K.T. is a co-founder and shareholder of BetaLife Pte Ltd but is not employed by BetaLife Pte Ltd. All other authors declare no conflict of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yasmin Abu Aqel and Aldana Alnesf contributed equally to this review.
==== Refs
References

1. Iynedjian PB Molecular physiology of mammalian glucokinase Cell Mol Life Sci 2009 66 1 27 42 10.1007/s00018-008-8322-9 18726182
Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27–42.18726182 10.1007/s00018-008-8322-9
2. Matschinsky FM Magnuson MA Zelent D Jetton TL Doliba N Han Y The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy Diabetes 2006 55 1 1 12 10.2337/diabetes.55.01.06.db05-0926 16380470
Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006;55(1):1–12.16380470 10.2337/diabetes.55.01.06.db05-0926
3. Matschinsky FM Wilson DF The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of langerhans Front Physiol 2019 10 148 10.3389/fphys.2019.00148 30949058
Matschinsky FM, Wilson DF. The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of langerhans. Front Physiol. 2019;10:148.30949058 10.3389/fphys.2019.00148
4. Matschinsky FM Ellerman JE Metabolism of glucose in the islets of Langerhans J Biol Chem 1968 243 10 2730 2736 10.1016/S0021-9258(18)93432-0 4870741
Matschinsky FM, Ellerman JE. Metabolism of glucose in the islets of Langerhans. J Biol Chem. 1968;243(10):2730–6.4870741 10.1016/S0021-9258(18)93432-0
5. Salas M Vinuela E Sols A Insulin-dependent synthesis of liver glucokinase in the rat J Biol Chem 1963 238 3535 3538 10.1016/S0021-9258(19)75303-4 14109182
Salas M, Vinuela E, Sols A. Insulin-dependent synthesis of liver glucokinase in the rat. J Biol Chem. 1963;238:3535–8.14109182 10.1016/S0021-9258(19)75303-4
6. Hattersley AT Turner RC Permutt MA Patel P Tanizawa Y Chiu KC Linkage of type 2 diabetes to the glucokinase gene Lancet 1992 339 8805 1307 1310 10.1016/0140-6736(92)91958-B 1349989
Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, Chiu KC, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet. 1992;339(8805):1307–10.1349989 10.1016/0140-6736(92)91958-B
7. Njolstad PR Sovik O Cuesta-Munoz A Bjorkhaug L Massa O Barbetti F Neonatal diabetes mellitus due to complete glucokinase deficiency N Engl J Med 2001 344 21 1588 1592 10.1056/NEJM200105243442104 11372010
Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344(21):1588–92.11372010 10.1056/NEJM200105243442104
8. Sternisha SM Miller BG Molecular and cellular regulation of human glucokinase Arch Biochem Biophys 2019 663 199 213 10.1016/j.abb.2019.01.011 30641049
Sternisha SM, Miller BG. Molecular and cellular regulation of human glucokinase. Arch Biochem Biophys. 2019;663:199–213.30641049 10.1016/j.abb.2019.01.011
9. Osbak KK Colclough K Saint-Martin C Beer NL Bellanne-Chantelot C Ellard S Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia Hum Mutat 2009 30 11 1512 1526 10.1002/humu.21110 19790256
Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11):1512–26.19790256 10.1002/humu.21110
10. Capuano M Garcia-Herrero CM Tinto N Carluccio C Capobianco V Coto I Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy PLoS ONE 2012 7 6 e38906 10.1371/journal.pone.0038906 22761713
Capuano M, Garcia-Herrero CM, Tinto N, Carluccio C, Capobianco V, Coto I, et al. Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy. PLoS ONE. 2012;7(6): e38906.22761713 10.1371/journal.pone.0038906
11. Lopez AP de Dios A Chiesa I Perez MS Frechtel GD Analysis of mutations in the glucokinase gene in people clinically characterized as MODY2 without a family history of diabetes Diabetes Res Clin Pract 2016 118 38 43 10.1016/j.diabres.2016.04.057 27289208
Lopez AP, de Dios A, Chiesa I, Perez MS, Frechtel GD. Analysis of mutations in the glucokinase gene in people clinically characterized as MODY2 without a family history of diabetes. Diabetes Res Clin Pract. 2016;118:38–43.27289208 10.1016/j.diabres.2016.04.057
12. Shoemaker AH Zienkiewicz J Moore DJ Clinical assessment of HNF1A and GCK variants and identification of a novel mutation causing MODY2 Diabetes Res Clin Pract 2012 96 2 e36 e39 10.1016/j.diabres.2012.01.032 22341299
Shoemaker AH, Zienkiewicz J, Moore DJ. Clinical assessment of HNF1A and GCK variants and identification of a novel mutation causing MODY2. Diabetes Res Clin Pract. 2012;96(2):e36–9.22341299 10.1016/j.diabres.2012.01.032
13. Jetton TL Liang Y Pettepher CC Zimmerman EC Cox FG Horvath K Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut J Biol Chem 1994 269 5 3641 3654 10.1016/S0021-9258(17)41910-7 8106409
Jetton TL, Liang Y, Pettepher CC, Zimmerman EC, Cox FG, Horvath K, et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J Biol Chem. 1994;269(5):3641–54.8106409 10.1016/S0021-9258(17)41910-7
14. Agius L Hormonal and metabolite regulation of hepatic glucokinase Annu Rev Nutr 2016 36 389 415 10.1146/annurev-nutr-071715-051145 27146014
Agius L. Hormonal and metabolite regulation of hepatic glucokinase. Annu Rev Nutr. 2016;36:389–415.27146014 10.1146/annurev-nutr-071715-051145
15. Kamata K Mitsuya M Nishimura T Eiki J Nagata Y Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase Structure 2004 12 3 429 438 10.1016/j.str.2004.02.005 15016359
Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004;12(3):429–38.15016359 10.1016/j.str.2004.02.005
16. Andreone TL Printz RL Pilkis SJ Magnuson MA Granner DK The amino acid sequence of rat liver glucokinase deduced from cloned cDNA J Biol Chem 1989 264 1 363 369 10.1016/S0021-9258(17)31266-8 2909525
Andreone TL, Printz RL, Pilkis SJ, Magnuson MA, Granner DK. The amino acid sequence of rat liver glucokinase deduced from cloned cDNA. J Biol Chem. 1989;264(1):363–9.2909525 10.1016/S0021-9258(17)31266-8
17. Aleshin AE Zeng C Bartunik HD Fromm HJ Honzatko RB Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate J Mol Biol 1998 282 2 345 357 10.1006/jmbi.1998.2017 9735292
Aleshin AE, Zeng C, Bartunik HD, Fromm HJ, Honzatko RB. Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate. J Mol Biol. 1998;282(2):345–57.9735292 10.1006/jmbi.1998.2017
18. Mitsuya M Kamata K Bamba M Watanabe H Sasaki Y Sasaki K Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators Bioorg Med Chem Lett 2009 19 10 2718 2721 10.1016/j.bmcl.2009.03.137 19362831
Mitsuya M, Kamata K, Bamba M, Watanabe H, Sasaki Y, Sasaki K, et al. Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators. Bioorg Med Chem Lett. 2009;19(10):2718–21.19362831 10.1016/j.bmcl.2009.03.137
19. Takahashi K Hashimoto N Nakama C Kamata K Sasaki K Yoshimoto R The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators Bioorg Med Chem 2009 17 19 7042 7051 10.1016/j.bmc.2009.05.037 19736020
Takahashi K, Hashimoto N, Nakama C, Kamata K, Sasaki K, Yoshimoto R, et al. The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators. Bioorg Med Chem. 2009;17(19):7042–51.19736020 10.1016/j.bmc.2009.05.037
20. Bebernitz GR Beaulieu V Dale BA Deacon R Duttaroy A Gao J Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes J Med Chem 2009 52 19 6142 6152 10.1021/jm900839k 19746978
Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, et al. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem. 2009;52(19):6142–52.19746978 10.1021/jm900839k
21. Petit P Antoine M Ferry G Boutin JA Lagarde A Gluais L The active conformation of human glucokinase is not altered by allosteric activators Acta Crystallogr D Biol Crystallogr 2011 67 Pt 11 929 935 10.1107/S0907444911036729 22101819
Petit P, Antoine M, Ferry G, Boutin JA, Lagarde A, Gluais L, et al. The active conformation of human glucokinase is not altered by allosteric activators. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 11):929–35.22101819 10.1107/S0907444911036729
22. Zhang J Li C Shi T Chen K Shen X Jiang H Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis PLoS ONE 2009 4 7 e6304 10.1371/journal.pone.0006304 19617908
Zhang J, Li C, Shi T, Chen K, Shen X, Jiang H. Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis. PLoS ONE. 2009;4(7): e6304.19617908 10.1371/journal.pone.0006304
23. Antoine M Boutin JA Ferry G Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states Biochemistry 2009 48 23 5466 5482 10.1021/bi900374c 19459610
Antoine M, Boutin JA, Ferry G. Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states. Biochemistry. 2009;48(23):5466–82.19459610 10.1021/bi900374c
24. Liu S Ammirati MJ Song X Knafels JD Zhang J Greasley SE Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations J Biol Chem 2012 287 17 13598 13610 10.1074/jbc.M111.274126 22298776
Liu S, Ammirati MJ, Song X, Knafels JD, Zhang J, Greasley SE, et al. Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations. J Biol Chem. 2012;287(17):13598–610.22298776 10.1074/jbc.M111.274126
25. Choi JM Seo MH Kyeong HH Kim E Kim HS Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase Proc Natl Acad Sci U S A 2013 110 25 10171 10176 10.1073/pnas.1300457110 23733961
Choi JM, Seo MH, Kyeong HH, Kim E, Kim HS. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci U S A. 2013;110(25):10171–6.23733961 10.1073/pnas.1300457110
26. Futamura M Hosaka H Kadotani A Shimazaki H Sasaki K Ohyama S An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism J Biol Chem 2006 281 49 37668 37674 10.1074/jbc.M605186200 17028192
Futamura M, Hosaka H, Kadotani A, Shimazaki H, Sasaki K, Ohyama S, et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem. 2006;281(49):37668–74.17028192 10.1074/jbc.M605186200
27. Anderka O Boyken J Aschenbach U Batzer A Boscheinen O Schmoll D Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors J Biol Chem 2008 283 46 31333 31340 10.1074/jbc.M805434200 18809676
Anderka O, Boyken J, Aschenbach U, Batzer A, Boscheinen O, Schmoll D. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem. 2008;283(46):31333–40.18809676 10.1074/jbc.M805434200
28. Beck T Miller BG Structural basis for regulation of human glucokinase by glucokinase regulatory protein Biochemistry 2013 52 36 6232 6239 10.1021/bi400838t 23957911
Beck T, Miller BG. Structural basis for regulation of human glucokinase by glucokinase regulatory protein. Biochemistry. 2013;52(36):6232–9.23957911 10.1021/bi400838t
29. Bosco D Meda P Iynedjian PB Glucokinase and glucokinase regulatory protein: mutual dependence for nuclear localization Biochem J 2000 348 Pt 1 215 222 10.1042/bj3480215 10794734
Bosco D, Meda P, Iynedjian PB. Glucokinase and glucokinase regulatory protein: mutual dependence for nuclear localization. Biochem J. 2000;348(Pt 1):215–22.10794734 10.1042/bj3480215
30. Raimondo A Rees MG Gloyn AL Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism Curr Opin Lipidol 2015 26 2 88 95 10.1097/MOL.0000000000000155 25692341
Raimondo A, Rees MG, Gloyn AL. Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr Opin Lipidol. 2015;26(2):88–95.25692341 10.1097/MOL.0000000000000155
31. Stride A Ellard S Clark P Shakespeare L Salzmann M Shepherd M Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers Diabetes Care 2005 28 7 1751 1756 10.2337/diacare.28.7.1751 15983330
Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28(7):1751–6.15983330 10.2337/diacare.28.7.1751
32. Sharma C Manjeshwar R Weinhouse S Effects of diet and insulin on glucose-adenosine triphosphate phosphotransferases of rat liver J Biol Chem 1963 238 3840 3845 10.1016/S0021-9258(18)51797-X 14086716
Sharma C, Manjeshwar R, Weinhouse S. Effects of diet and insulin on glucose-adenosine triphosphate phosphotransferases of rat liver. J Biol Chem. 1963;238:3840–5.14086716 10.1016/S0021-9258(18)51797-X
33. Tu J Tuch BE Expression of glucokinase in glucose-unresponsive human fetal pancreatic islet-like cell clusters J Clin Endocrinol Metab 1997 82 3 943 948 9062511
Tu J, Tuch BE. Expression of glucokinase in glucose-unresponsive human fetal pancreatic islet-like cell clusters. J Clin Endocrinol Metab. 1997;82(3):943–8.9062511
34. Richardson CC Hussain K Jones PM Persaud S Lobner K Boehm A Low levels of glucose transporters and K+ATP channels in human pancreatic beta cells early in development Diabetologia 2007 50 5 1000 1005 10.1007/s00125-007-0644-x 17380317
Richardson CC, Hussain K, Jones PM, Persaud S, Lobner K, Boehm A, et al. Low levels of glucose transporters and K+ATP channels in human pancreatic beta cells early in development. Diabetologia. 2007;50(5):1000–5.17380317 10.1007/s00125-007-0644-x
35. Dettmer R Niwolik I Mehmeti I Jorns A Naujok O New hPSC SOX9 and INS reporter cell lines facilitate the observation and optimization of differentiation into insulin-producing cells Stem Cell Rev Rep 2021 17 6 2193 2209 10.1007/s12015-021-10232-9 34415483
Dettmer R, Niwolik I, Mehmeti I, Jorns A, Naujok O. New hPSC SOX9 and INS reporter cell lines facilitate the observation and optimization of differentiation into insulin-producing cells. Stem Cell Rev Rep. 2021;17(6):2193–209.34415483 10.1007/s12015-021-10232-9
36. Ramond C Beydag-Tasoz BS Azad A van de Bunt M Petersen MBK Beer NL Understanding human fetal pancreas development using subpopulation sorting, RNA sequencing and single-cell profiling Development 2018 145 16 dev165480 10.1242/dev.165480 30042179
Ramond C, Beydag-Tasoz BS, Azad A, van de Bunt M, Petersen MBK, Beer NL, et al. Understanding human fetal pancreas development using subpopulation sorting, RNA sequencing and single-cell profiling. Development. 2018;145(16):dev165480.30042179 10.1242/dev.165480
37. Dean PM Matthews EK Glucose-induced electrical activity in pancreatic islet cells J Physiol 1970 210 2 255 264 10.1113/jphysiol.1970.sp009207 5501259
Dean PM, Matthews EK. Glucose-induced electrical activity in pancreatic islet cells. J Physiol. 1970;210(2):255–64.5501259 10.1113/jphysiol.1970.sp009207
38. Meissner HP Schmelz H Membrane potential of beta-cells in pancreatic islets Pflugers Arch 1974 351 3 195 206 10.1007/BF00586918 4608967
Meissner HP, Schmelz H. Membrane potential of beta-cells in pancreatic islets. Pflugers Arch. 1974;351(3):195–206.4608967 10.1007/BF00586918
39. Bedoya FJ Meglasson MD Wilson JM Matschinsky FM Radiometric oil well assay for glucokinase in microscopic structures Anal Biochem 1985 144 2 504 513 10.1016/0003-2697(85)90147-2 3887980
Bedoya FJ, Meglasson MD, Wilson JM, Matschinsky FM. Radiometric oil well assay for glucokinase in microscopic structures. Anal Biochem. 1985;144(2):504–13.3887980 10.1016/0003-2697(85)90147-2
40. Bedoya FJ Wilson JM Ghosh AK Finegold D Matschinsky FM The glucokinase glucose sensor in human pancreatic islet tissue Diabetes 1986 35 1 61 67 10.2337/diab.35.1.61 3510141
Bedoya FJ, Wilson JM, Ghosh AK, Finegold D, Matschinsky FM. The glucokinase glucose sensor in human pancreatic islet tissue. Diabetes. 1986;35(1):61–7.3510141 10.2337/diab.35.1.61
41. Matschinsky FM Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm Diabetes 1996 45 2 223 241 10.2337/diab.45.2.223 8549869
Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes. 1996;45(2):223–41.8549869 10.2337/diab.45.2.223
42. Matschinsky FM Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics Diabetes 2002 51 Suppl 3 S394 404 10.2337/diabetes.51.2007.S394 12475782
Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes. 2002;51(Suppl 3):S394-404.12475782 10.2337/diabetes.51.2007.S394
43. Niemeyer H de la Luz CM Rabajille E Ureta T Clark-Turri L Penaranda J Sigmoidal kinetics of glucokinase Enzyme 1975 20 6 321 333 10.1159/000458957 1193069
Niemeyer H, de la Luz CM, Rabajille E, Ureta T, Clark-Turri L, Penaranda J. Sigmoidal kinetics of glucokinase. Enzyme. 1975;20(6):321–33.1193069 10.1159/000458957
44. Nakamura A Terauchi Y Present status of clinical deployment of glucokinase activators J Diabetes Investig 2015 6 2 124 132 10.1111/jdi.12294 25802718
Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators. J Diabetes Investig. 2015;6(2):124–32.25802718 10.1111/jdi.12294
45. Tiedge M Steffeck H Elsner M Lenzen S Metabolic regulation, activity state, and intracellular binding of glucokinase in insulin-secreting cells Diabetes 1999 48 3 514 523 10.2337/diabetes.48.3.514 10078551
Tiedge M, Steffeck H, Elsner M, Lenzen S. Metabolic regulation, activity state, and intracellular binding of glucokinase in insulin-secreting cells. Diabetes. 1999;48(3):514–23.10078551 10.2337/diabetes.48.3.514
46. Toyoda Y Yoshie S Shironoguchi H Miwa I Glucokinase is concentrated in insulin-secretory granules of pancreatic B-cells Histochem Cell Biol 1999 112 1 35 40 10.1007/s004180050389 10461810
Toyoda Y, Yoshie S, Shironoguchi H, Miwa I. Glucokinase is concentrated in insulin-secretory granules of pancreatic B-cells. Histochem Cell Biol. 1999;112(1):35–40.10461810 10.1007/s004180050389
47. Kim WH Lee JW Suh YH Hong SH Choi JS Lim JH Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells Diabetes 2005 54 9 2602 2611 10.2337/diabetes.54.9.2602 16123348
Kim WH, Lee JW, Suh YH, Hong SH, Choi JS, Lim JH, et al. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. Diabetes. 2005;54(9):2602–11.16123348 10.2337/diabetes.54.9.2602
48. Baltrusch S Lenzen S Okar DA Lange AJ Tiedge M Characterization of glucokinase-binding protein epitopes by a phage-displayed peptide library. Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel interaction partner J Biol Chem 2001 276 47 43915 43923 10.1074/jbc.M105470200 11522786
Baltrusch S, Lenzen S, Okar DA, Lange AJ, Tiedge M. Characterization of glucokinase-binding protein epitopes by a phage-displayed peptide library. Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel interaction partner. J Biol Chem. 2001;276(47):43915–23.11522786 10.1074/jbc.M105470200
49. Danial NN Gramm CF Scorrano L Zhang CY Krauss S Ranger AM BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis Nature 2003 424 6951 952 956 10.1038/nature01825 12931191
Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424(6951):952–6.12931191 10.1038/nature01825
50. Fu A Alvarez-Perez JC Avizonis D Kin T Ficarro SB Choi DW Glucose-dependent partitioning of arginine to the urea cycle protects beta-cells from inflammation Nat Metab 2020 2 5 432 446 10.1038/s42255-020-0199-4 32694660
Fu A, Alvarez-Perez JC, Avizonis D, Kin T, Ficarro SB, Choi DW, et al. Glucose-dependent partitioning of arginine to the urea cycle protects beta-cells from inflammation. Nat Metab. 2020;2(5):432–46.32694660 10.1038/s42255-020-0199-4
51. Ljubicic S Polak K Fu A Wiwczar J Szlyk B Chang Y Phospho-BAD BH3 mimicry protects beta cells and restores functional beta cell mass in diabetes Cell Rep 2015 10 4 497 504 10.1016/j.celrep.2014.12.056 25640178
Ljubicic S, Polak K, Fu A, Wiwczar J, Szlyk B, Chang Y, et al. Phospho-BAD BH3 mimicry protects beta cells and restores functional beta cell mass in diabetes. Cell Rep. 2015;10(4):497–504.25640178 10.1016/j.celrep.2014.12.056
52. Guo T Mao Y Li H Wang X Xu W Song R Characterization of the gene expression profile of heterozygous liver-specific glucokinase knockout mice at a young age Biomed Pharmacother 2012 66 8 587 596 10.1016/j.biopha.2012.07.002 23085254
Guo T, Mao Y, Li H, Wang X, Xu W, Song R, et al. Characterization of the gene expression profile of heterozygous liver-specific glucokinase knockout mice at a young age. Biomed Pharmacother. 2012;66(8):587–96.23085254 10.1016/j.biopha.2012.07.002
53. De Vos A Heimberg H Quartier E Huypens P Bouwens L Pipeleers D Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression J Clin Invest 1995 96 5 2489 2495 10.1172/JCI118308 7593639
De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest. 1995;96(5):2489–95.7593639 10.1172/JCI118308
54. Doliba NM Qin W Vatamaniuk MZ Li C Zelent D Najafi H Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine Am J Physiol Endocrinol Metab 2004 286 5 E834 E843 10.1152/ajpendo.00292.2003 14736703
Doliba NM, Qin W, Vatamaniuk MZ, Li C, Zelent D, Najafi H, et al. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine. Am J Physiol Endocrinol Metab. 2004;286(5):E834–43.14736703 10.1152/ajpendo.00292.2003
55. Henzen C Monogenic diabetes mellitus due to defects in insulin secretion Swiss Med Wkly 2012 142 w13690 23037711
Henzen C. Monogenic diabetes mellitus due to defects in insulin secretion. Swiss Med Wkly. 2012;142: w13690.23037711
56. Magnuson MA Glucokinase gene structure. Functional implications of molecular genetic studies Diabetes 1990 39 5 523 527 10.2337/diab.39.5.523 2185104
Magnuson MA. Glucokinase gene structure. Functional implications of molecular genetic studies. Diabetes. 1990;39(5):523–7.2185104 10.2337/diab.39.5.523
57. Niswender KD Postic C Shiota M Jetton TL Magnuson MA Effects of altered glucokinase gene copy number on blood glucose homoeostasis Biochem Soc Trans 1997 25 1 113 117 10.1042/bst0250113 9056854
Niswender KD, Postic C, Shiota M, Jetton TL, Magnuson MA. Effects of altered glucokinase gene copy number on blood glucose homoeostasis. Biochem Soc Trans. 1997;25(1):113–7.9056854 10.1042/bst0250113
58. Porat S Weinberg-Corem N Tornovsky-Babaey S Schyr-Ben-Haroush R Hija A Stolovich-Rain M Control of pancreatic beta cell regeneration by glucose metabolism Cell Metab 2011 13 4 440 449 10.1016/j.cmet.2011.02.012 21459328
Porat S, Weinberg-Corem N, Tornovsky-Babaey S, Schyr-Ben-Haroush R, Hija A, Stolovich-Rain M, et al. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab. 2011;13(4):440–9.21459328 10.1016/j.cmet.2011.02.012
59. Terauchi Y Takamoto I Kubota N Matsui J Suzuki R Komeda K Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance J Clin Invest 2007 117 1 246 257 10.1172/JCI17645 17200721
Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest. 2007;117(1):246–57.17200721 10.1172/JCI17645
60. Kassem S Bhandari S Rodriguez-Bada P Motaghedi R Heyman M Garcia-Gimeno MA Large islets, beta-cell proliferation, and a glucokinase mutation N Engl J Med 2010 362 14 1348 1350 10.1056/NEJMc0909845 20375417
Kassem S, Bhandari S, Rodriguez-Bada P, Motaghedi R, Heyman M, Garcia-Gimeno MA, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010;362(14):1348–50.20375417 10.1056/NEJMc0909845
61. Shirakawa J Amo K Ohminami H Orime K Togashi Y Ito Y Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes J Biol Chem 2011 286 29 25467 25476 10.1074/jbc.M110.217216 21613229
Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, et al. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011;286(29):25467–76.21613229 10.1074/jbc.M110.217216
62. Shirakawa J Togashi Y Sakamoto E Kaji M Tajima K Orime K Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells Diabetes 2013 62 10 3448 3458 10.2337/db13-0052 23801577
Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes. 2013;62(10):3448–58.23801577 10.2337/db13-0052
63. Shirakawa J Translational research on human pancreatic beta-cell mass expansion for the treatment of diabetes Diabetol Int 2021 12 4 349 355 10.1007/s13340-021-00531-4 34567917
Shirakawa J. Translational research on human pancreatic beta-cell mass expansion for the treatment of diabetes. Diabetol Int. 2021;12(4):349–55.34567917 10.1007/s13340-021-00531-4
64. Aukrust I Bjorkhaug L Negahdar M Molnes J Johansson BB Muller Y SUMOylation of pancreatic glucokinase regulates its cellular stability and activity J Biol Chem 2013 288 8 5951 5962 10.1074/jbc.M112.393769 23297408
Aukrust I, Bjorkhaug L, Negahdar M, Molnes J, Johansson BB, Muller Y, et al. SUMOylation of pancreatic glucokinase regulates its cellular stability and activity. J Biol Chem. 2013;288(8):5951–62.23297408 10.1074/jbc.M112.393769
65. Bjorkhaug L Molnes J Sovik O Njolstad PR Flatmark T Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent cotranslational proteasomal degradation J Biol Chem 2007 282 31 22757 22764 10.1074/jbc.M700517200 17561510
Bjorkhaug L, Molnes J, Sovik O, Njolstad PR, Flatmark T. Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent cotranslational proteasomal degradation. J Biol Chem. 2007;282(31):22757–64.17561510 10.1074/jbc.M700517200
66. Watada H Kajimoto Y Miyagawa J Hanafusa T Hamaguchi K Matsuoka T PDX-1 induces insulin and glucokinase gene expressions in alphaTC1 clone 6 cells in the presence of betacellulin Diabetes 1996 45 12 1826 1831 10.2337/diab.45.12.1826 8922372
Watada H, Kajimoto Y, Miyagawa J, Hanafusa T, Hamaguchi K, Matsuoka T, et al. PDX-1 induces insulin and glucokinase gene expressions in alphaTC1 clone 6 cells in the presence of betacellulin. Diabetes. 1996;45(12):1826–31.8922372 10.2337/diab.45.12.1826
67. Habener JF Kemp DM Thomas MK Minireview: transcriptional regulation in pancreatic development Endocrinology 2005 146 3 1025 1034 10.1210/en.2004-1576 15604203
Habener JF, Kemp DM, Thomas MK. Minireview: transcriptional regulation in pancreatic development. Endocrinology. 2005;146(3):1025–34.15604203 10.1210/en.2004-1576
68. Ahlgren U Jonsson J Jonsson L Simu K Edlund H beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes Genes Dev 1998 12 12 1763 1768 10.1101/gad.12.12.1763 9637677
Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 1998;12(12):1763–8.9637677 10.1101/gad.12.12.1763
69. Bae JS Kim TH Kim MY Park JM Ahn YH Transcriptional regulation of glucose sensors in pancreatic beta-cells and liver: an update Sensors (Basel) 2010 10 5 5031 5053 10.3390/s100505031 22399922
Bae JS, Kim TH, Kim MY, Park JM, Ahn YH. Transcriptional regulation of glucose sensors in pancreatic beta-cells and liver: an update. Sensors (Basel). 2010;10(5):5031–53.22399922 10.3390/s100505031
70. Bedoya FJ Oberholtzer JC Matschinsky FM Glucokinase in B-cell-depleted islets of Langerhans J Histochem Cytochem 1987 35 10 1089 1093 10.1177/35.10.3305701 3305701
Bedoya FJ, Oberholtzer JC, Matschinsky FM. Glucokinase in B-cell-depleted islets of Langerhans. J Histochem Cytochem. 1987;35(10):1089–93.3305701 10.1177/35.10.3305701
71. Hedeskov CJ Mechanism of glucose-induced insulin secretion Physiol Rev 1980 60 2 442 509 10.1152/physrev.1980.60.2.442 6247727
Hedeskov CJ. Mechanism of glucose-induced insulin secretion. Physiol Rev. 1980;60(2):442–509.6247727 10.1152/physrev.1980.60.2.442
72. Unger RH Orci L Glucagon and the A cell: physiology and pathophysiology (first two parts) N Engl J Med 1981 304 25 1518 1524 10.1056/NEJM198106183042504 7015132
Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med. 1981;304(25):1518–24.7015132 10.1056/NEJM198106183042504
73. Pipeleers DG Schuit FC Van Schravendijk CF Van de Winkel M Interplay of nutrients and hormones in the regulation of glucagon release Endocrinology 1985 117 3 817 823 10.1210/endo-117-3-817 2862020
Pipeleers DG, Schuit FC, Van Schravendijk CF, Van de Winkel M. Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology. 1985;117(3):817–23.2862020 10.1210/endo-117-3-817
74. Heimberg H De Vos A Pipeleers D Thorens B Schuit F Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization J Biol Chem 1995 270 15 8971 8975 10.1074/jbc.270.15.8971 7721807
Heimberg H, De Vos A, Pipeleers D, Thorens B, Schuit F. Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization. J Biol Chem. 1995;270(15):8971–5.7721807 10.1074/jbc.270.15.8971
75. Li J Yu Q Ahooghalandari P Gribble FM Reimann F Tengholm A Submembrane ATP and Ca2+ kinetics in alpha-cells: unexpected signaling for glucagon secretion FASEB J 2015 29 8 3379 3388 10.1096/fj.14-265918 25911612
Li J, Yu Q, Ahooghalandari P, Gribble FM, Reimann F, Tengholm A, et al. Submembrane ATP and Ca2+ kinetics in alpha-cells: unexpected signaling for glucagon secretion. FASEB J. 2015;29(8):3379–88.25911612 10.1096/fj.14-265918
76. Diao J Allister EM Koshkin V Lee SC Bhattacharjee A Tang C UCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival Proc Natl Acad Sci U S A 2008 105 33 12057 12062 10.1073/pnas.0710434105 18701716
Diao J, Allister EM, Koshkin V, Lee SC, Bhattacharjee A, Tang C, et al. UCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival. Proc Natl Acad Sci U S A. 2008;105(33):12057–62.18701716 10.1073/pnas.0710434105
77. Moede T Leibiger B Vaca Sanchez P Dare E Kohler M Muhandiramlage TP Glucokinase intrinsically regulates glucose sensing and glucagon secretion in pancreatic alpha cells Sci Rep 2020 10 1 20145 10.1038/s41598-020-76863-z 33214580
Moede T, Leibiger B, Vaca Sanchez P, Dare E, Kohler M, Muhandiramlage TP, et al. Glucokinase intrinsically regulates glucose sensing and glucagon secretion in pancreatic alpha cells. Sci Rep. 2020;10(1):20145.33214580 10.1038/s41598-020-76863-z
78. Basco D Zhang Q Salehi A Tarasov A Dolci W Herrera P alpha-cell glucokinase suppresses glucose-regulated glucagon secretion Nat Commun 2018 9 1 546 10.1038/s41467-018-03034-0 29416045
Basco D, Zhang Q, Salehi A, Tarasov A, Dolci W, Herrera P, et al. alpha-cell glucokinase suppresses glucose-regulated glucagon secretion. Nat Commun. 2018;9(1):546.29416045 10.1038/s41467-018-03034-0
79. Matschinsky FM Pagliara AS Stillings SN Hover BA Glucose and ATP levels in pancreatic islet tissue of normal and diabetic rats J Clin Invest 1976 58 5 1193 1200 10.1172/JCI108572 136453
Matschinsky FM, Pagliara AS, Stillings SN, Hover BA. Glucose and ATP levels in pancreatic islet tissue of normal and diabetic rats. J Clin Invest. 1976;58(5):1193–200.136453 10.1172/JCI108572
80. Heimberg H De Vos A Moens K Quartier E Bouwens L Pipeleers D The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells Proc Natl Acad Sci U S A 1996 93 14 7036 7041 10.1073/pnas.93.14.7036 8692940
Heimberg H, De Vos A, Moens K, Quartier E, Bouwens L, Pipeleers D, et al. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells. Proc Natl Acad Sci U S A. 1996;93(14):7036–41.8692940 10.1073/pnas.93.14.7036
81. Wajngot A Alvarsson M Glaser A Efendic S Luthman H Grill V Glucose potentiation of arginine-induced insulin secretion is impaired in subjects with a glucokinase Glu256Lys mutation Diabetes 1994 43 12 1402 1406 10.2337/diab.43.12.1402 7958490
Wajngot A, Alvarsson M, Glaser A, Efendic S, Luthman H, Grill V. Glucose potentiation of arginine-induced insulin secretion is impaired in subjects with a glucokinase Glu256Lys mutation. Diabetes. 1994;43(12):1402–6.7958490 10.2337/diab.43.12.1402
82. Guenat E Seematter G Philippe J Temler E Jequier E Tappy L Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations Diabetes Metab 2000 26 5 377 384 11119017
Guenat E, Seematter G, Philippe J, Temler E, Jequier E, Tappy L. Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations. Diabetes Metab. 2000;26(5):377–84.11119017
83. Agius L Glucokinase and molecular aspects of liver glycogen metabolism Biochem J 2008 414 1 1 18 10.1042/BJ20080595 18651836
Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008;414(1):1–18.18651836 10.1042/BJ20080595
84. Nordlie RC Foster JD Lange AJ Regulation of glucose production by the liver Annu Rev Nutr 1999 19 379 406 10.1146/annurev.nutr.19.1.379 10448530
Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. Annu Rev Nutr. 1999;19:379–406.10448530 10.1146/annurev.nutr.19.1.379
85. Iynedjian PB Gjinovci A Renold AE Stimulation by insulin of glucokinase gene transcription in liver of diabetic rats J Biol Chem 1988 263 2 740 744 10.1016/S0021-9258(19)35415-8 3275657
Iynedjian PB, Gjinovci A, Renold AE. Stimulation by insulin of glucokinase gene transcription in liver of diabetic rats. J Biol Chem. 1988;263(2):740–4.3275657 10.1016/S0021-9258(19)35415-8
86. Iynedjian PB Mammalian glucokinase and its gene Biochem J 1993 293 Pt 1 1 13 10.1042/bj2930001 8392329
Iynedjian PB. Mammalian glucokinase and its gene. Biochem J. 1993;293(Pt 1):1–13.8392329 10.1042/bj2930001
87. Van Schaftingen E A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate Eur J Biochem 1989 179 1 179 184 10.1111/j.1432-1033.1989.tb14538.x 2917560
Van Schaftingen E. A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate. Eur J Biochem. 1989;179(1):179–84.2917560 10.1111/j.1432-1033.1989.tb14538.x
88. van Schaftingen E Vandercammen A Detheux M Davies DR The regulatory protein of liver glucokinase Adv Enzyme Regul 1992 32 133 148 10.1016/0065-2571(92)90013-P 1496915
van Schaftingen E, Vandercammen A, Detheux M, Davies DR. The regulatory protein of liver glucokinase. Adv Enzyme Regul. 1992;32:133–48.1496915 10.1016/0065-2571(92)90013-P
89. Shiota C Coffey J Grimsby J Grippo JF Magnuson MA Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase J Biol Chem 1999 274 52 37125 37130 10.1074/jbc.274.52.37125 10601273
Shiota C, Coffey J, Grimsby J, Grippo JF, Magnuson MA. Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J Biol Chem. 1999;274(52):37125–30.10601273 10.1074/jbc.274.52.37125
90. Arden C Baltrusch S Agius L Glucokinase regulatory protein is associated with mitochondria in hepatocytes FEBS Lett 2006 580 8 2065 2070 10.1016/j.febslet.2006.03.009 16542652
Arden C, Baltrusch S, Agius L. Glucokinase regulatory protein is associated with mitochondria in hepatocytes. FEBS Lett. 2006;580(8):2065–70.16542652 10.1016/j.febslet.2006.03.009
91. Johansson BB Fjeld K Solheim MH Shirakawa J Zhang E Keindl M Nuclear import of glucokinase in pancreatic beta-cells is mediated by a nuclear localization signal and modulated by SUMOylation Mol Cell Endocrinol 2017 454 146 157 10.1016/j.mce.2017.06.020 28648619
Johansson BB, Fjeld K, Solheim MH, Shirakawa J, Zhang E, Keindl M, et al. Nuclear import of glucokinase in pancreatic beta-cells is mediated by a nuclear localization signal and modulated by SUMOylation. Mol Cell Endocrinol. 2017;454:146–57.28648619 10.1016/j.mce.2017.06.020
92. Pautsch A Stadler N Lohle A Rist W Berg A Glocker L Crystal structure of glucokinase regulatory protein Biochemistry 2013 52 20 3523 3531 10.1021/bi4000782 23621087
Pautsch A, Stadler N, Lohle A, Rist W, Berg A, Glocker L, et al. Crystal structure of glucokinase regulatory protein. Biochemistry. 2013;52(20):3523–31.23621087 10.1021/bi4000782
93. Casey AK Miller BG Kinetic basis of carbohydrate-mediated inhibition of human glucokinase by the glucokinase regulatory protein Biochemistry 2016 55 21 2899 2902 10.1021/acs.biochem.6b00349 27174229
Casey AK, Miller BG. Kinetic basis of carbohydrate-mediated inhibition of human glucokinase by the glucokinase regulatory protein. Biochemistry. 2016;55(21):2899–902.27174229 10.1021/acs.biochem.6b00349
94. Park JM Kim TH Jo SH Kim MY Ahn YH Acetylation of glucokinase regulatory protein decreases glucose metabolism by suppressing glucokinase activity Sci Rep 2015 5 17395 10.1038/srep17395 26620281
Park JM, Kim TH, Jo SH, Kim MY, Ahn YH. Acetylation of glucokinase regulatory protein decreases glucose metabolism by suppressing glucokinase activity. Sci Rep. 2015;5:17395.26620281 10.1038/srep17395
95. Matschinsky FM Glaser B Magnuson MA Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities Diabetes 1998 47 3 307 315 10.2337/diabetes.47.3.307 9519733
Matschinsky FM, Glaser B, Magnuson MA. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes. 1998;47(3):307–15.9519733 10.2337/diabetes.47.3.307
96. Bali D Svetlanov A Lee HW Fusco-DeMane D Leiser M Li B Animal model for maturity-onset diabetes of the young generated by disruption of the mouse glucokinase gene J Biol Chem 1995 270 37 21464 21467 10.1074/jbc.270.37.21464 7665557
Bali D, Svetlanov A, Lee HW, Fusco-DeMane D, Leiser M, Li B, et al. Animal model for maturity-onset diabetes of the young generated by disruption of the mouse glucokinase gene. J Biol Chem. 1995;270(37):21464–7.7665557 10.1074/jbc.270.37.21464
97. Bell GI Pilkis SJ Weber IT Polonsky KS Glucokinase mutations, insulin secretion, and diabetes mellitus Annu Rev Physiol 1996 58 171 186 10.1146/annurev.ph.58.030196.001131 8815790
Bell GI, Pilkis SJ, Weber IT, Polonsky KS. Glucokinase mutations, insulin secretion, and diabetes mellitus. Annu Rev Physiol. 1996;58:171–86.8815790 10.1146/annurev.ph.58.030196.001131
98. Gidh-Jain M Takeda J Xu LZ Lange AJ Vionnet N Stoffel M Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships Proc Natl Acad Sci U S A 1993 90 5 1932 1936 10.1073/pnas.90.5.1932 8446612
Gidh-Jain M, Takeda J, Xu LZ, Lange AJ, Vionnet N, Stoffel M, et al. Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. Proc Natl Acad Sci U S A. 1993;90(5):1932–6.8446612 10.1073/pnas.90.5.1932
99. Pilkis SJ Weber IT Harrison RW Bell GI Glucokinase: structural analysis of a protein involved in susceptibility to diabetes J Biol Chem 1994 269 35 21925 21928 10.1016/S0021-9258(17)31733-7 8071309
Pilkis SJ, Weber IT, Harrison RW, Bell GI. Glucokinase: structural analysis of a protein involved in susceptibility to diabetes. J Biol Chem. 1994;269(35):21925–8.8071309 10.1016/S0021-9258(17)31733-7
100. Stoffel M Froguel P Takeda J Zouali H Vionnet N Nishi S Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus Proc Natl Acad Sci U S A 1992 89 16 7698 7702 10.1073/pnas.89.16.7698 1502186
Stoffel M, Froguel P, Takeda J, Zouali H, Vionnet N, Nishi S, et al. Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus. Proc Natl Acad Sci U S A. 1992;89(16):7698–702.1502186 10.1073/pnas.89.16.7698
101. Takeda J Gidh-Jain M Xu LZ Froguel P Velho G Vaxillaire M Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants J Biol Chem 1993 268 20 15200 15204 10.1016/S0021-9258(18)82456-5 8325892
Takeda J, Gidh-Jain M, Xu LZ, Froguel P, Velho G, Vaxillaire M, et al. Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants. J Biol Chem. 1993;268(20):15200–4.8325892 10.1016/S0021-9258(18)82456-5
102. Ellard S Beards F Allen LI Shepherd M Ballantyne E Harvey R A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria Diabetologia 2000 43 2 250 253 10.1007/s001250050038 10753050
Ellard S, Beards F, Allen LI, Shepherd M, Ballantyne E, Harvey R, et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia. 2000;43(2):250–3.10753050 10.1007/s001250050038
103. Thomson KL Gloyn AL Colclough K Batten M Allen LI Beards F Identification of 21 novel glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY) Hum Mutat 2003 22 5 417 10.1002/humu.9186 14517956
Thomson KL, Gloyn AL, Colclough K, Batten M, Allen LI, Beards F, et al. Identification of 21 novel glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY). Hum Mutat. 2003;22(5):417.14517956 10.1002/humu.9186
104. Edghill EL Dix RJ Flanagan SE Bingley PJ Hattersley AT Ellard S HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months Diabetes 2006 55 6 1895 1898 10.2337/db06-0094 16731860
Edghill EL, Dix RJ, Flanagan SE, Bingley PJ, Hattersley AT, Ellard S, et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes. 2006;55(6):1895–8.16731860 10.2337/db06-0094
105. Rubio-Cabezas O Klupa T Malecki MT Consortium C Permanent neonatal diabetes mellitus–the importance of diabetes differential diagnosis in neonates and infants Eur J Clin Invest 2011 41 3 323 333 10.1111/j.1365-2362.2010.02409.x 21054355
Rubio-Cabezas O, Klupa T, Malecki MT, Consortium C. Permanent neonatal diabetes mellitus–the importance of diabetes differential diagnosis in neonates and infants. Eur J Clin Invest. 2011;41(3):323–33.21054355 10.1111/j.1365-2362.2010.02409.x
106. Porter JR Shaw NJ Barrett TG Hattersley AT Ellard S Gloyn AL Permanent neonatal diabetes in an Asian infant J Pediatr 2005 146 1 131 133 10.1016/j.jpeds.2004.09.008 15644838
Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL. Permanent neonatal diabetes in an Asian infant. J Pediatr. 2005;146(1):131–3.15644838 10.1016/j.jpeds.2004.09.008
107. Njolstad PR Sagen JV Bjorkhaug L Odili S Shehadeh N Bakry D Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway Diabetes 2003 52 11 2854 2860 10.2337/diabetes.52.11.2854 14578306
Njolstad PR, Sagen JV, Bjorkhaug L, Odili S, Shehadeh N, Bakry D, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003;52(11):2854–60.14578306 10.2337/diabetes.52.11.2854
108. Mustaf M El-Atawi K Zakaria A Elhalik M Bastak F Neonate with permanent neonatal diabetes mellitus; a very rare homozygous missense mutation in the glucokinase gene J Pediatr Neonatal Care 2019 9 1–2019 12 14
Mustaf M, El-Atawi K, Zakaria A, Elhalik M, Bastak F. Neonate with permanent neonatal diabetes mellitus; a very rare homozygous missense mutation in the glucokinase gene. J Pediatr Neonatal Care. 2019;9(1–2019):12–4.
109. Garcia-Herrero CM Galan M Vincent O Flandez B Gargallo M Delgado-Alvarez E Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity Diabetologia 2007 50 2 325 333 10.1007/s00125-006-0542-7 17186219
Garcia-Herrero CM, Galan M, Vincent O, Flandez B, Gargallo M, Delgado-Alvarez E, et al. Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity. Diabetologia. 2007;50(2):325–33.17186219 10.1007/s00125-006-0542-7
110. Raimondo A Chakera AJ Thomsen SK Colclough K Barrett A De Franco E Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability Hum Mol Genet 2014 23 24 6432 6440 10.1093/hmg/ddu360 25015100
Raimondo A, Chakera AJ, Thomsen SK, Colclough K, Barrett A, De Franco E, et al. Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability. Hum Mol Genet. 2014;23(24):6432–40.25015100 10.1093/hmg/ddu360
111. Chakera AJ Steele AM Gloyn AL Shepherd MH Shields B Ellard S Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation Diabetes Care 2015 38 7 1383 1392 10.2337/dc14-2769 26106223
Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care. 2015;38(7):1383–92.26106223 10.2337/dc14-2769
112. Steele AM Shields BM Wensley KJ Colclough K Ellard S Hattersley AT Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia JAMA 2014 311 3 279 286 10.1001/jama.2013.283980 24430320
Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311(3):279–86.24430320 10.1001/jama.2013.283980
113. Ellard S Thomas K Edghill EL Owens M Ambye L Cropper J Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young Diabetologia 2007 50 11 2313 2317 10.1007/s00125-007-0798-6 17828387
Ellard S, Thomas K, Edghill EL, Owens M, Ambye L, Cropper J, et al. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia. 2007;50(11):2313–7.17828387 10.1007/s00125-007-0798-6
114. Froguel P Vaxillaire M Sun F Velho G Zouali H Butel MO Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus Nature 1992 356 6365 162 164 10.1038/356162a0 1545870
Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356(6365):162–4.1545870 10.1038/356162a0
115. Murphy R Ellard S Hattersley AT Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes Nat Clin Pract Endocrinol Metab 2008 4 4 200 213 10.1038/ncpendmet0778 18301398
Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(4):200–13.18301398 10.1038/ncpendmet0778
116. Byrne MM Sturis J Clement K Vionnet N Pueyo ME Stoffel M Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations J Clin Invest 1994 93 3 1120 1130 10.1172/JCI117064 8132752
Byrne MM, Sturis J, Clement K, Vionnet N, Pueyo ME, Stoffel M, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest. 1994;93(3):1120–30.8132752 10.1172/JCI117064
117. Velho G Petersen KF Perseghin G Hwang JH Rothman DL Pueyo ME Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects J Clin Invest 1996 98 8 1755 1761 10.1172/JCI118974 8878425
Velho G, Petersen KF, Perseghin G, Hwang JH, Rothman DL, Pueyo ME, et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J Clin Invest. 1996;98(8):1755–61.8878425 10.1172/JCI118974
118. Tappy L Dussoix P Iynedjian P Henry S Schneiter P Zahnd G Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene Diabetes 1997 46 2 204 208 10.2337/diab.46.2.204 9000695
Tappy L, Dussoix P, Iynedjian P, Henry S, Schneiter P, Zahnd G, et al. Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene. Diabetes. 1997;46(2):204–8.9000695 10.2337/diab.46.2.204
119. Stride A Vaxillaire M Tuomi T Barbetti F Njolstad PR Hansen T The genetic abnormality in the beta cell determines the response to an oral glucose load Diabetologia 2002 45 3 427 435 10.1007/s00125-001-0770-9 11914749
Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45(3):427–35.11914749 10.1007/s00125-001-0770-9
120. Sun F Knebelmann B Pueyo ME Zouali H Lesage S Vaxillaire M Deletion of the donor splice site of intron 4 in the glucokinase gene causes maturity-onset diabetes of the young J Clin Invest 1993 92 3 1174 1180 10.1172/JCI116687 8376578
Sun F, Knebelmann B, Pueyo ME, Zouali H, Lesage S, Vaxillaire M, et al. Deletion of the donor splice site of intron 4 in the glucokinase gene causes maturity-onset diabetes of the young. J Clin Invest. 1993;92(3):1174–80.8376578 10.1172/JCI116687
121. Gasperikova D Tribble ND Stanik J Huckova M Misovicova N van de Bunt M Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans Diabetes 2009 58 8 1929 1935 10.2337/db09-0070 19411616
Gasperikova D, Tribble ND, Stanik J, Huckova M, Misovicova N, van de Bunt M, et al. Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans. Diabetes. 2009;58(8):1929–35.19411616 10.2337/db09-0070
122. Snider KE Becker S Boyajian L Shyng SL MacMullen C Hughes N Genotype and phenotype correlations in 417 children with congenital hyperinsulinism J Clin Endocrinol Metab 2013 98 2 E355 E363 10.1210/jc.2012-2169 23275527
Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N, et al. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab. 2013;98(2):E355–63.23275527 10.1210/jc.2012-2169
123. Sayed S Langdon DR Odili S Chen P Buettger C Schiffman AB Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations Diabetes 2009 58 6 1419 1427 10.2337/db08-1792 19336674
Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, et al. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes. 2009;58(6):1419–27.19336674 10.2337/db08-1792
124. Glaser B Kesavan P Heyman M Davis E Cuesta A Buchs A Familial hyperinsulinism caused by an activating glucokinase mutation N Engl J Med 1998 338 4 226 230 10.1056/NEJM199801223380404 9435328
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998;338(4):226–30.9435328 10.1056/NEJM199801223380404
125. Gloyn AL Noordam K Willemsen MA Ellard S Lam WW Campbell IW Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations Diabetes 2003 52 9 2433 2440 10.2337/diabetes.52.9.2433 12941786
Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes. 2003;52(9):2433–40.12941786 10.2337/diabetes.52.9.2433
126. Christesen HB Jacobsen BB Odili S Buettger C Cuesta-Munoz A Hansen T The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy Diabetes 2002 51 4 1240 1246 10.2337/diabetes.51.4.1240 11916951
Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240–6.11916951 10.2337/diabetes.51.4.1240
127. Randle PJ Glucokinase and candidate genes for type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 1993 36 4 269 275 10.1007/BF00400227 8386682
Randle PJ. Glucokinase and candidate genes for type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993;36(4):269–75.8386682 10.1007/BF00400227
128. Pino MF Kim KA Shelton KD Lindner J Odili S Li C Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations J Biol Chem 2007 282 18 13906 13916 10.1074/jbc.M610094200 17353190
Pino MF, Kim KA, Shelton KD, Lindner J, Odili S, Li C, et al. Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations. J Biol Chem. 2007;282(18):13906–16.17353190 10.1074/jbc.M610094200
129. Pedelini L Garcia-Gimeno MA Marina A Gomez-Zumaquero JM Rodriguez-Bada P Lopez-Enriquez S Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations Protein Sci 2005 14 8 2080 2086 10.1110/ps.051485205 15987895
Pedelini L, Garcia-Gimeno MA, Marina A, Gomez-Zumaquero JM, Rodriguez-Bada P, Lopez-Enriquez S, et al. Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations. Protein Sci. 2005;14(8):2080–6.15987895 10.1110/ps.051485205
130. Davis EA Cuesta-Munoz A Raoul M Buettger C Sweet I Moates M Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis Diabetologia 1999 42 10 1175 1186 10.1007/s001250051289 10525657
Davis EA, Cuesta-Munoz A, Raoul M, Buettger C, Sweet I, Moates M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia. 1999;42(10):1175–86.10525657 10.1007/s001250051289
131. Negahdar M Aukrust I Johansson BB Molnes J Molven A Matschinsky FM GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation Biochim Biophys Acta 2012 1822 11 1705 1715 10.1016/j.bbadis.2012.07.005 22820548
Negahdar M, Aukrust I, Johansson BB, Molnes J, Molven A, Matschinsky FM, et al. GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation. Biochim Biophys Acta. 2012;1822(11):1705–15.22820548 10.1016/j.bbadis.2012.07.005
132. Burke CV Buettger CW Davis EA McClane SJ Matschinsky FM Raper SE Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI) Biochem J 1999 342 Pt 2 345 352 10.1042/bj3420345 10455021
Burke CV, Buettger CW, Davis EA, McClane SJ, Matschinsky FM, Raper SE. Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI). Biochem J. 1999;342(Pt 2):345–52.10455021 10.1042/bj3420345
133. Arden C Trainer A de la Iglesia N Scougall KT Gloyn AL Lange AJ Cell biology assessment of glucokinase mutations V62M and G72R in pancreatic beta-cells: evidence for cellular instability of catalytic activity Diabetes 2007 56 7 1773 1782 10.2337/db06-1151 17389332
Arden C, Trainer A, de la Iglesia N, Scougall KT, Gloyn AL, Lange AJ, et al. Cell biology assessment of glucokinase mutations V62M and G72R in pancreatic beta-cells: evidence for cellular instability of catalytic activity. Diabetes. 2007;56(7):1773–82.17389332 10.2337/db06-1151
134. Gloyn AL Odili S Zelent D Buettger C Castleden HA Steele AM Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young J Biol Chem 2005 280 14 14105 14113 10.1074/jbc.M413146200 15677479
Gloyn AL, Odili S, Zelent D, Buettger C, Castleden HA, Steele AM, et al. Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young. J Biol Chem. 2005;280(14):14105–13.15677479 10.1074/jbc.M413146200
135. Heredia VV Carlson TJ Garcia E Sun S Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations J Biol Chem 2006 281 52 40201 40207 10.1074/jbc.M607987200 17082186
Heredia VV, Carlson TJ, Garcia E, Sun S. Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations. J Biol Chem. 2006;281(52):40201–7.17082186 10.1074/jbc.M607987200
136. Miller SP Anand GR Karschnia EJ Bell GI LaPorte DC Lange AJ Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype Diabetes 1999 48 8 1645 1651 10.2337/diabetes.48.8.1645 10426385
Miller SP, Anand GR, Karschnia EJ, Bell GI, LaPorte DC, Lange AJ. Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype. Diabetes. 1999;48(8):1645–51.10426385 10.2337/diabetes.48.8.1645
137. Yorifuji T Higuchi S Kawakita R Hosokawa Y Aoyama T Murakami A Genetic basis of early-onset, maturity-onset diabetes of the young-like diabetes in Japan and features of patients without mutations in the major MODY genes: dominance of maternal inheritance Pediatr Diabetes 2018 19 7 1164 1172 10.1111/pedi.12714 29927023
Yorifuji T, Higuchi S, Kawakita R, Hosokawa Y, Aoyama T, Murakami A, et al. Genetic basis of early-onset, maturity-onset diabetes of the young-like diabetes in Japan and features of patients without mutations in the major MODY genes: dominance of maternal inheritance. Pediatr Diabetes. 2018;19(7):1164–72.29927023 10.1111/pedi.12714
138. Kesavan P Wang L Davis E Cuesta A Sweet I Niswender K Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2) Biochem J 1997 322 Pt 1 57 63 10.1042/bj3220057 9078243
Kesavan P, Wang L, Davis E, Cuesta A, Sweet I, Niswender K, et al. Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2). Biochem J. 1997;322(Pt 1):57–63.9078243 10.1042/bj3220057
139. Sagen JV Odili S Bjorkhaug L Zelent D Buettger C Kwagh J From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation Diabetes 2006 55 6 1713 1722 10.2337/db05-1513 16731834
Sagen JV, Odili S, Bjorkhaug L, Zelent D, Buettger C, Kwagh J, et al. From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes. 2006;55(6):1713–22.16731834 10.2337/db05-1513
140. Aykut A Karaca E Onay H Goksen D Cetinkalp S Eren E Analysis of the GCK gene in 79 MODY type 2 patients: a multicenter Turkish study, mutation profile and description of twenty novel mutations Gene 2018 641 186 189 10.1016/j.gene.2017.10.057 29056535
Aykut A, Karaca E, Onay H, Goksen D, Cetinkalp S, Eren E, et al. Analysis of the GCK gene in 79 MODY type 2 patients: a multicenter Turkish study, mutation profile and description of twenty novel mutations. Gene. 2018;641:186–9.29056535 10.1016/j.gene.2017.10.057
141. Aloi C Salina A Minuto N Tallone R Lugani F Mascagni A Glucokinase mutations in pediatric patients with impaired fasting glucose Acta Diabetol 2017 54 10 913 923 10.1007/s00592-017-1021-y 28726111
Aloi C, Salina A, Minuto N, Tallone R, Lugani F, Mascagni A, et al. Glucokinase mutations in pediatric patients with impaired fasting glucose. Acta Diabetol. 2017;54(10):913–23.28726111 10.1007/s00592-017-1021-y
142. Li X Ting TH Sheng H Liang CL Shao Y Jiang M Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY) BMC Pediatr 2018 18 1 101 10.1186/s12887-018-1060-8 29510678
Li X, Ting TH, Sheng H, Liang CL, Shao Y, Jiang M, et al. Genetic and clinical characteristics of Chinese children with Glucokinase-maturity-onset diabetes of the young (GCK-MODY). BMC Pediatr. 2018;18(1):101.29510678 10.1186/s12887-018-1060-8
143. Galan M Vincent O Roncero I Azriel S Boix-Pallares P Delgado-Alvarez E Effects of novel maturity-onset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability Biochem J 2006 393 Pt 1 389 396 10.1042/BJ20051137 16173921
Galan M, Vincent O, Roncero I, Azriel S, Boix-Pallares P, Delgado-Alvarez E, et al. Effects of novel maturity-onset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability. Biochem J. 2006;393(Pt 1):389–96.16173921 10.1042/BJ20051137
144. Estalella I Garcia-Gimeno MA Marina A Castano L Sanz P Biochemical characterization of novel glucokinase mutations isolated from Spanish maturity-onset diabetes of the young (MODY2) patients J Hum Genet 2008 53 5 460 466 10.1007/s10038-008-0271-5 18322640
Estalella I, Garcia-Gimeno MA, Marina A, Castano L, Sanz P. Biochemical characterization of novel glucokinase mutations isolated from Spanish maturity-onset diabetes of the young (MODY2) patients. J Hum Genet. 2008;53(5):460–6.18322640 10.1007/s10038-008-0271-5
145. Froguel P Zouali H Vionnet N Velho G Vaxillaire M Sun F Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus N Engl J Med 1993 328 10 697 702 10.1056/NEJM199303113281005 8433729
Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med. 1993;328(10):697–702.8433729 10.1056/NEJM199303113281005
146. Zelent B Odili S Buettger C Shiota C Grimsby J Taub R Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence Biochem J 2008 413 2 269 280 10.1042/BJ20071718 18370929
Zelent B, Odili S, Buettger C, Shiota C, Grimsby J, Taub R, et al. Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence. Biochem J. 2008;413(2):269–80.18370929 10.1042/BJ20071718
147. Stoffel M Patel P Lo YM Hattersley AT Lucassen AM Page R Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes Nat Genet 1992 2 2 153 156 10.1038/ng1092-153 1303265
Stoffel M, Patel P, Lo YM, Hattersley AT, Lucassen AM, Page R, et al. Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes. Nat Genet. 1992;2(2):153–6.1303265 10.1038/ng1092-153
148. Marotta DE Anand GR Anderson TA Miller SP Okar DA Levitt DG Identification and characterization of the ATP-binding site in human pancreatic glucokinase Arch Biochem Biophys 2005 436 1 23 31 10.1016/j.abb.2005.01.018 15752705
Marotta DE, Anand GR, Anderson TA, Miller SP, Okar DA, Levitt DG, et al. Identification and characterization of the ATP-binding site in human pancreatic glucokinase. Arch Biochem Biophys. 2005;436(1):23–31.15752705 10.1016/j.abb.2005.01.018
149. Jha S Siddiqui S Waghdhare S Dubey S Krishna S Subramanian K Identification of a novel glucokinase mutation in an Indian woman with GCK-MODY Lancet Diabetes Endocrinol 2016 4 4 302 10.1016/S2213-8587(16)00040-1 27016322
Jha S, Siddiqui S, Waghdhare S, Dubey S, Krishna S, Subramanian K, et al. Identification of a novel glucokinase mutation in an Indian woman with GCK-MODY. Lancet Diabetes Endocrinol. 2016;4(4):302.27016322 10.1016/S2213-8587(16)00040-1
150. Aqel YWA Ali G Elsayed AK Al-Khawaga S Hussain K Abdelalim EM Generation of two human iPSC lines from patients with maturity-onset diabetes of the young type 2 (MODY2) and permanent neonatal diabetes due to mutations in the GCK gene Stem Cell Res 2020 48 101991 10.1016/j.scr.2020.101991 32971462
Aqel YWA, Ali G, Elsayed AK, Al-Khawaga S, Hussain K, Abdelalim EM. Generation of two human iPSC lines from patients with maturity-onset diabetes of the young type 2 (MODY2) and permanent neonatal diabetes due to mutations in the GCK gene. Stem Cell Res. 2020;48: 101991.32971462 10.1016/j.scr.2020.101991
151. Turkkahraman D Bircan I Tribble ND Akcurin S Ellard S Gloyn AL Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy J Pediatr 2008 153 1 122 126 10.1016/j.jpeds.2007.12.037 18571549
Turkkahraman D, Bircan I, Tribble ND, Akcurin S, Ellard S, Gloyn AL. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. J Pediatr. 2008;153(1):122–6.18571549 10.1016/j.jpeds.2007.12.037
152. Christesen HB Tribble ND Molven A Siddiqui J Sandal T Brusgaard K Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation Eur J Endocrinol 2008 159 1 27 34 10.1530/EJE-08-0203 18450771
Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, et al. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol. 2008;159(1):27–34.18450771 10.1530/EJE-08-0203
153. Wabitsch M Lahr G Van de Bunt M Marchant C Lindner M von Puttkamer J Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy Diabet Med 2007 24 12 1393 1399 10.1111/j.1464-5491.2007.02285.x 17976205
Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, et al. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med. 2007;24(12):1393–9.17976205 10.1111/j.1464-5491.2007.02285.x
154. Cuesta-Munoz AL Huopio H Otonkoski T Gomez-Zumaquero JM Nanto-Salonen K Rahier J Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation Diabetes 2004 53 8 2164 2168 10.2337/diabetes.53.8.2164 15277402
Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes. 2004;53(8):2164–8.15277402 10.2337/diabetes.53.8.2164
155. Inoue M Sakuraba Y Motegi H Kubota N Toki H Matsui J A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program Hum Mol Genet 2004 13 11 1147 1157 10.1093/hmg/ddh133 15102714
Inoue M, Sakuraba Y, Motegi H, Kubota N, Toki H, Matsui J, et al. A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program. Hum Mol Genet. 2004;13(11):1147–57.15102714 10.1093/hmg/ddh133
156. Toye AA Moir L Hugill A Bentley L Quarterman J Mijat V A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene Diabetes 2004 53 6 1577 1583 10.2337/diabetes.53.6.1577 15161764
Toye AA, Moir L, Hugill A, Bentley L, Quarterman J, Mijat V, et al. A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene. Diabetes. 2004;53(6):1577–83.15161764 10.2337/diabetes.53.6.1577
157. Tam CH Ho JS Wang Y Lee HM Lam VK Germer S Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects PLoS ONE 2010 5 7 e11428 10.1371/journal.pone.0011428 20628598
Tam CH, Ho JS, Wang Y, Lee HM, Lam VK, Germer S, et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects. PLoS ONE. 2010;5(7): e11428.20628598 10.1371/journal.pone.0011428
158. Ansari N Ramachandran V Mohamad NA Salim E Ismail P Hazmi M Association of GCK (rs1799884), GCKR (rs780094), and G6PC2 (rs560887) gene polymorphisms with type 2 diabetes among Malay ethnics Glob Med Genet 2023 10 1 12 18 10.1055/s-0042-1760384 36703777
Ansari N, Ramachandran V, Mohamad NA, Salim E, Ismail P, Hazmi M, et al. Association of GCK (rs1799884), GCKR (rs780094), and G6PC2 (rs560887) gene polymorphisms with type 2 diabetes among Malay ethnics. Glob Med Genet. 2023;10(1):12–8.36703777 10.1055/s-0042-1760384
159. Zhang YL Tan XH Xiao MF Li H Mao YQ Yang X Establishment of liver specific glucokinase gene knockout mice: a new animal model for screening anti-diabetic drugs Acta Pharmacol Sin 2004 25 12 1659 1665 15569412
Zhang YL, Tan XH, Xiao MF, Li H, Mao YQ, Yang X, et al. Establishment of liver specific glucokinase gene knockout mice: a new animal model for screening anti-diabetic drugs. Acta Pharmacol Sin. 2004;25(12):1659–65.15569412
160. Ferre T Pujol A Riu E Bosch F Valera A Correction of diabetic alterations by glucokinase Proc Natl Acad Sci U S A 1996 93 14 7225 7230 10.1073/pnas.93.14.7225 8692973
Ferre T, Pujol A, Riu E, Bosch F, Valera A. Correction of diabetic alterations by glucokinase. Proc Natl Acad Sci U S A. 1996;93(14):7225–30.8692973 10.1073/pnas.93.14.7225
161. Niswender KD Li J Powell MR Loos KR Roberts RM Keisler DH Effect of variants of interferon-tau with mutations near the carboxyl terminus on luteal life span in sheep Biol Reprod 1997 56 1 214 220 10.1095/biolreprod56.1.214 9002652
Niswender KD, Li J, Powell MR, Loos KR, Roberts RM, Keisler DH, et al. Effect of variants of interferon-tau with mutations near the carboxyl terminus on luteal life span in sheep. Biol Reprod. 1997;56(1):214–20.9002652 10.1095/biolreprod56.1.214
162. O'Doherty RM Lehman DL Telemaque-Potts S Newgard CB Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia Diabetes 1999 48 10 2022 2027 10.2337/diabetes.48.10.2022 10512368
O’Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes. 1999;48(10):2022–7.10512368 10.2337/diabetes.48.10.2022
163. Desai UJ Slosberg ED Boettcher BR Caplan SL Fanelli B Stephan Z Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression Diabetes 2001 50 10 2287 2295 10.2337/diabetes.50.10.2287 11574410
Desai UJ, Slosberg ED, Boettcher BR, Caplan SL, Fanelli B, Stephan Z, et al. Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. Diabetes. 2001;50(10):2287–95.11574410 10.2337/diabetes.50.10.2287
164. Grupe A Hultgren B Ryan A Ma YH Bauer M Stewart TA Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis Cell 1995 83 1 69 78 10.1016/0092-8674(95)90235-X 7553875
Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell. 1995;83(1):69–78.7553875 10.1016/0092-8674(95)90235-X
165. Postic C Shiota M Niswender KD Jetton TL Chen Y Moates JM Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase J Biol Chem 1999 274 1 305 315 10.1074/jbc.274.1.305 9867845
Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274(1):305–15.9867845 10.1074/jbc.274.1.305
166. Terauchi Y Sakura H Yasuda K Iwamoto K Takahashi N Ito K Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose J Biol Chem 1995 270 51 30253 30256 10.1074/jbc.270.51.30253 8530440
Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Takahashi N, Ito K, et al. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem. 1995;270(51):30253–6.8530440 10.1074/jbc.270.51.30253
167. Niswender KD Shiota M Postic C Cherrington AD Magnuson MA Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism J Biol Chem 1997 272 36 22570 22575 10.1074/jbc.272.36.22570 9278411
Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA. Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem. 1997;272(36):22570–5.9278411 10.1074/jbc.272.36.22570
168. Ferre T Riu E Franckhauser S Agudo J Bosch F Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance Diabetologia 2003 46 12 1662 1668 10.1007/s00125-003-1244-z 14614559
Ferre T, Riu E, Franckhauser S, Agudo J, Bosch F. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia. 2003;46(12):1662–8.14614559 10.1007/s00125-003-1244-z
169. Chen KH Doliba N May CL Roman J Ustione A Tembo T Genetic activation of glucokinase in a minority of pancreatic beta cells causes hypoglycemia in mice Life Sci 2022 309 120952 10.1016/j.lfs.2022.120952 36100080
Chen KH, Doliba N, May CL, Roman J, Ustione A, Tembo T, et al. Genetic activation of glucokinase in a minority of pancreatic beta cells causes hypoglycemia in mice. Life Sci. 2022;309: 120952.36100080 10.1016/j.lfs.2022.120952
170. Tornovsky-Babeay S Weinberg-Corem N Ben-Haroush Schyr R Avrahami D Lavi J Feleke E Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes Diabetologia 2021 64 5 1133 1143 10.1007/s00125-021-05390-x 33558985
Tornovsky-Babeay S, Weinberg-Corem N, Ben-Haroush Schyr R, Avrahami D, Lavi J, Feleke E, et al. Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes. Diabetologia. 2021;64(5):1133–43.33558985 10.1007/s00125-021-05390-x
171. Balboa D Otonkoski T Human pluripotent stem cell based islet models for diabetes research Best Pract Res Clin Endocrinol Metab 2015 29 6 899 909 10.1016/j.beem.2015.10.012 26696518
Balboa D, Otonkoski T. Human pluripotent stem cell based islet models for diabetes research. Best Pract Res Clin Endocrinol Metab. 2015;29(6):899–909.26696518 10.1016/j.beem.2015.10.012
172. Rodriguez-Diaz R Molano RD Weitz JR Abdulreda MH Berman DM Leibiger B Paracrine interactions within the pancreatic islet determine the glycemic set point Cell Metab 2018 27 3 549 558 10.1016/j.cmet.2018.01.015 29514065
Rodriguez-Diaz R, Molano RD, Weitz JR, Abdulreda MH, Berman DM, Leibiger B, et al. Paracrine interactions within the pancreatic islet determine the glycemic set point. Cell Metab. 2018;27(3):549–58.29514065 10.1016/j.cmet.2018.01.015
173. Amirruddin NS Low BSJ Lee KO Tai ES Teo AKK New insights into human beta cell biology using human pluripotent stem cells Semin Cell Dev Biol 2020 103 31 40 10.1016/j.semcdb.2019.11.004 31757584
Amirruddin NS, Low BSJ, Lee KO, Tai ES, Teo AKK. New insights into human beta cell biology using human pluripotent stem cells. Semin Cell Dev Biol. 2020;103:31–40.31757584 10.1016/j.semcdb.2019.11.004
174. Abdelalim EM Modeling different types of diabetes using human pluripotent stem cells Cell Mol Life Sci 2021 78 6 2459 2483 10.1007/s00018-020-03710-9 33242105
Abdelalim EM. Modeling different types of diabetes using human pluripotent stem cells. Cell Mol Life Sci. 2021;78(6):2459–83.33242105 10.1007/s00018-020-03710-9
175. Memon B Abdelalim EM Toward precision medicine with human pluripotent stem cells for diabetes Stem Cells Transl Med 2022 11 7 704 714 10.1093/stcltm/szac030 35640144
Memon B, Abdelalim EM. Toward precision medicine with human pluripotent stem cells for diabetes. Stem Cells Transl Med. 2022;11(7):704–14.35640144 10.1093/stcltm/szac030
176. Lithovius V Otonkoski T Stem cell based models in congenital hyperinsulinism - perspective on practicalities and possibilities Front Endocrinol (Lausanne) 2022 13 837450 10.3389/fendo.2022.837450 35250887
Lithovius V, Otonkoski T. Stem cell based models in congenital hyperinsulinism - perspective on practicalities and possibilities. Front Endocrinol (Lausanne). 2022;13: 837450.35250887 10.3389/fendo.2022.837450
